151 results on '"Masarone D"'
Search Results
2. Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry
- Author
-
Bossone, E., Arcopinto, M., Iacoviello, M., Triggiani, V., Cacciatore, F., Maiello, C., Limongelli, G., Masarone, D., Perticone, F., Sciacqua, A., Perrone-Filardi, P., Mancini, A., Volterrani, M., Vriz, O., Castello, R., Passantino, A., Campo, M., Modesti, P. A., De Giorgi, A., Monte, I., Puzzo, A., Ballotta, A., Caliendo, L., D’Assante, R., Marra, A. M., Salzano, A., Suzuki, T., Cittadini, A., and On behalf of TOSCA Investigators
- Published
- 2018
- Full Text
- View/download PDF
3. How to fill the gap in the symptomatic HF patient journey between optimal medical therapy and advanced heart failure treatment: two Italian surveys
- Author
-
Spadotto, A, primary, Ziacchi, M, additional, Ghio, S, additional, Pellegrino, M, additional, Masarone, D, additional, Caracciolo, M, additional, Inserra, C A, additional, Ammirati, F, additional, Ciccarelli, M, additional, Colivicchi, F, additional, Bianchi, S, additional, Oliva, F, additional, Biffi, M, additional, and Sinagra, G, additional
- Published
- 2023
- Full Text
- View/download PDF
4. C53 EFFECTS OF CARDIAC CONTRACTILITY MODULATION THERAPY ON LEFT VENTRICLE GLOBAL LONGITUDINAL STRAIN AND MYOCARDIAL MECHANO–ENERGETIC EFFICIENCY IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
- Author
-
Martucci, M, primary, Kittleson, M, additional, De Vivo, S, additional, D’Onofrio, A, additional, Ammendola, E, additional, Nigro, G, additional, Contaldi, C, additional, Errigo, V, additional, Pacileo, G, additional, and Masarone, D, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry
- Author
-
Asselbergs F. W., Sammani A., Elliott P., Gimeno J. R., Tavazzi L., Tendera M., Kaski J. P., Maggioni A. P., Rubis P. P., Jurcut R., Helio T., Calo L., Sinagra G., Zdravkovic M., Olivotto I., Kavoliuniene A., Laroche C., Caforio A. L. P., Charron P., Komissarova S., Chakova N., Niyazova S., Linhart A., Kuchynka P., Palecek T., Podzimkova J., Fikrle M., Nemecek E., Bundgaard H., Tfelt-Hansen J., Theilade J., Thune J. J., Axelsson A., Mogensen J., Henriksen F., Hey T., Nielsen S. K., Videbaek L., Andreasen S., Arnsted H., Saad A., Ali M., Lommi J., Nieminennew M. S., Dubourg O., Mansencal N., Arslan M., Siam Tsieu V., Damy T., Guellich A., Guendouz S., Tissot C. M., Lamine A., Rappeneau S., Hagege A., Desnos M., Bachet A., Hamzaoui M., Isnard R., Legrand L., Maupain C., Gandjbakhch E., Kerneis M., Pruny J. -F., Bauer A., Pfeiffer B., Felix S. B., Dorr M., Kaczmarek S., Lehnert K., Pedersen A. -L., Beug D., Bruder M., Bohm M., Kindermann I., Linicus Y., Werner C., Neurath B., Schild-Ungerbuehler M., Seggewiss H., Neugebauer A., McKeown P., Muir A., McOsker J., Jardine T., Divine G., Lorenzini M., Watkinson O., Wicks E., Iqbal H., Mohiddin S., O'Mahony C., Sekri N., Carr-White G., Bueser T., Rajani R., Clack L., Damm J., Jones S., Sanchez-Vidal R., Smith M., Walters T., Wilson K., Rosmini S., Anastasakis A., Ritsatos K., Vlagkouli V., Forster T., Sepp R., Borbas J., Nagy V., Tringer A., Kakonyi K., Szabo L. A., Maleki M., Noohi Bezanjani F., Amin A., Naderi N., Parsaee M., Taghavi S., Ghadrdoost B., Jafari S., Khoshavi M., Rapezzi C., Biagini E., Corsini A., Gagliardi C., Graziosi M., Longhi S., Milandri A., Ragni L., Palmieri S., Arretini A., Castelli G., Cecchi F., Fornaro A., Tomberli B., Spirito P., Devoto E., Della Bella P., Maccabelli G., Sala S., Guarracini F., Peretto G., Russo M. G., Calabro R., Pacileo G., Limongelli G., Masarone D., Pazzanese V., Rea A., Rubino M., Tramonte S., Valente F., Caiazza M., Cirillo A., Del Giorno G., Esposito A., Gravino R., Marrazzo T., Trimarco B., Losi M. -A., Di Nardo C., Giamundo A., Musella F., Pacelli F., Scatteia A., Canciello G., Caforio A., Iliceto S., Calore C., Leoni L., Perazzolo Marra M., Rigato I., Tarantini G., Schiavo A., Testolina M., Arbustini E., Di Toro A., Giuliani L. P., Serio A., Fedele F., Frustaci A., Alfarano M., Chimenti C., Drago F., Baban A., Lanzillo C., Martino A., Uguccioni M., Zachara E., Halasz G., Re F., Carriere C., Merlo M., Ramani F., Krivickiene A., Tamuleviciute-Prasciene E., Viezelis M., Celutkiene J., Balkeviciene L., Laukyte M., Paleviciute E., Pinto Y., Wilde A., Van Der Heijden J., Van Laake L., De Jonge N., Hassink R., Kirkels J. H., Ajuluchukwu J., Olusegun-Joseph A., Ekure E., Mizia-Stec K., Czekaj A., Sikora-Puz A., Skoczynska A., Wybraniec M., Rubis P., Dziewiecka E., Wisniowska-Smialek S., Bilinska Z., Chmielewski P., Foss-Nieradko B., Michalak E., Stepien-Wojno M., Mazek B., Rocha Lopes L., Almeida A. R., Cruz I., Gomes A. C., Pereira A. R., Brito D., Madeira H., Francisco A. R., Menezes M., Moldovan O., Oliveira Guimaraes T., Silva D., Ginghina C., Mursa A., Popescu B. A., Apetrei E., Militaru S., Mircea Coman I., Frigy A., Fogarasi Z., Kocsis I., Szabo I. A., Fehervari L., Nikitin I., Resnik E., Komissarova M., Lazarev V., Shebzukhova M., Ustyuzhanin D., Blagova O., Alieva I., Kulikova V., Lutokhina Y., Pavlenko E., Varionchik N., Ristic A. D., Seferovic P. M., Veljic I., Zivkovic I., Milinkovic I., Pavlovic A., Radovanovic G., Simeunovic D., Aleksic M., Djokic J., Hinic S., Klasnja S., Mircetic K., Monserrat L., Fernandez X., Garcia-Giustiniani D., Larranaga J. M., Ortiz-Genga M., Barriales-Villa R., Martinez-Veira C., Veira E., Cequier A., Salazar-Mendiguchia J., Manito N., Gonzalez J., Fernandez-Aviles F., Medrano C., Yotti R., Cuenca S., Espinosa M. A., Mendez I., Zatarain E., Alvarez R., Garcia-Pavia P., Briceno A., Cobo-Marcos M., Dominguez F., De Teresa Galvan E., Garcia Pinilla J. M., Abdeselam-Mohamed N., Lopez-Garrido M. A., Morcillo Hidalgo L., Ortega-Jimenez M. V., Robles Mezcua A., Guijarro-Contreras A., Gomez-Garcia D., Robles-Mezcua M., Gimeno Blanes J. R., Castro F. J., Munoz Esparza C., Sabater Molina M., Sorli Garcia M., Lopez Cuenca D., Ripoll-Vera T., Alvarez J., Nunez J., Gomez Y., Sanchez Fernandez P. L., Villacorta E., Avila C., Bravo L., Diaz-Pelaez E., Gallego-Delgado M., Garcia-Cuenllas L., Plata B., Lopez-Haldon J. E., Pena Pena M. L., Cantero Perez E. M., Zorio E., Arnau M. A., Sanz J., Marques-Sulex E., University Medical Center [Utrecht], University College of London [London] (UCL), Hospital Univeristario Virgen de la Arrixaca, University Hospital of Ferrara and Maria Cecilia Hospital, Medical University of Silesia, Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Chair of Medical Biochemistry, Jagiellonian University - Medical College, Chair of Medical Biochemistry, Emergency Hospital Floreasca Bucharest, Emergency Hospital Floreasca Bucharest, 8 Calea Floresca, Sector 1, 014461 Bucharest, Romania, University of Helsinki, Policlinico Casilino (Ospedale Policlinico Casilino), University of Trieste, University of Belgrade [Belgrade], Careggi University Hospital, Lithuanian University of health Sciences [Kaunas], Universita degli Studi di Padova, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hospital Clínico Universitario Virgen de la Arrixaca = University Hospital Virgen de la Arrixaca [Murcia], Medical University of Silesia (SUM), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Università degli studi di Trieste = University of Trieste, Università degli Studi di Padova = University of Padua (Unipd), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), HAL-SU, Gestionnaire, Asselbergs, F. W., Sammani, A., Elliott, P., Gimeno, J. R., Tavazzi, L., Tendera, M., Kaski, J. P., Maggioni, A. P., Rubis, P. P., Jurcut, R., Helio, T., Calo, L., Sinagra, G., Zdravkovic, M., Olivotto, I., Kavoliuniene, A., Laroche, C., Caforio, A. L. P., Charron, P., Komissarova, S., Chakova, N., Niyazova, S., Linhart, A., Kuchynka, P., Palecek, T., Podzimkova, J., Fikrle, M., Nemecek, E., Bundgaard, H., Tfelt-Hansen, J., Theilade, J., Thune, J. J., Axelsson, A., Mogensen, J., Henriksen, F., Hey, T., Nielsen, S. K., Videbaek, L., Andreasen, S., Arnsted, H., Saad, A., Ali, M., Lommi, J., Nieminennew, M. S., Dubourg, O., Mansencal, N., Arslan, M., Siam Tsieu, V., Damy, T., Guellich, A., Guendouz, S., Tissot, C. M., Lamine, A., Rappeneau, S., Hagege, A., Desnos, M., Bachet, A., Hamzaoui, M., Isnard, R., Legrand, L., Maupain, C., Gandjbakhch, E., Kerneis, M., Pruny, J. -F., Bauer, A., Pfeiffer, B., Felix, S. B., Dorr, M., Kaczmarek, S., Lehnert, K., Pedersen, A. -L., Beug, D., Bruder, M., Bohm, M., Kindermann, I., Linicus, Y., Werner, C., Neurath, B., Schild-Ungerbuehler, M., Seggewiss, H., Neugebauer, A., Mckeown, P., Muir, A., Mcosker, J., Jardine, T., Divine, G., Lorenzini, M., Watkinson, O., Wicks, E., Iqbal, H., Mohiddin, S., O'Mahony, C., Sekri, N., Carr-White, G., Bueser, T., Rajani, R., Clack, L., Damm, J., Jones, S., Sanchez-Vidal, R., Smith, M., Walters, T., Wilson, K., Rosmini, S., Anastasakis, A., Ritsatos, K., Vlagkouli, V., Forster, T., Sepp, R., Borbas, J., Nagy, V., Tringer, A., Kakonyi, K., Szabo, L. A., Maleki, M., Noohi Bezanjani, F., Amin, A., Naderi, N., Parsaee, M., Taghavi, S., Ghadrdoost, B., Jafari, S., Khoshavi, M., Rapezzi, C., Biagini, E., Corsini, A., Gagliardi, C., Graziosi, M., Longhi, S., Milandri, A., Ragni, L., Palmieri, S., Arretini, A., Castelli, G., Cecchi, F., Fornaro, A., Tomberli, B., Spirito, P., Devoto, E., Della Bella, P., Maccabelli, G., Sala, S., Guarracini, F., Peretto, G., Russo, M. G., Calabro, R., Pacileo, G., Limongelli, G., Masarone, D., Pazzanese, V., Rea, A., Rubino, M., Tramonte, S., Valente, F., Caiazza, M., Cirillo, A., Del Giorno, G., Esposito, A., Gravino, R., Marrazzo, T., Trimarco, B., Losi, M. -A., Di Nardo, C., Giamundo, A., Musella, F., Pacelli, F., Scatteia, A., Canciello, G., Caforio, A., Iliceto, S., Calore, C., Leoni, L., Perazzolo Marra, M., Rigato, I., Tarantini, G., Schiavo, A., Testolina, M., Arbustini, E., Di Toro, A., Giuliani, L. P., Serio, A., Fedele, F., Frustaci, A., Alfarano, M., Chimenti, C., Drago, F., Baban, A., Lanzillo, C., Martino, A., Uguccioni, M., Zachara, E., Halasz, G., Re, F., Carriere, C., Merlo, M., Ramani, F., Krivickiene, A., Tamuleviciute-Prasciene, E., Viezelis, M., Celutkiene, J., Balkeviciene, L., Laukyte, M., Paleviciute, E., Pinto, Y., Wilde, A., Van Der Heijden, J., Van Laake, L., De Jonge, N., Hassink, R., Kirkels, J. H., Ajuluchukwu, J., Olusegun-Joseph, A., Ekure, E., Mizia-Stec, K., Czekaj, A., Sikora-Puz, A., Skoczynska, A., Wybraniec, M., Rubis, P., Dziewiecka, E., Wisniowska-Smialek, S., Bilinska, Z., Chmielewski, P., Foss-Nieradko, B., Michalak, E., Stepien-Wojno, M., Mazek, B., Rocha Lopes, L., Almeida, A. R., Cruz, I., Gomes, A. C., Pereira, A. R., Brito, D., Madeira, H., Francisco, A. R., Menezes, M., Moldovan, O., Oliveira Guimaraes, T., Silva, D., Ginghina, C., Mursa, A., Popescu, B. A., Apetrei, E., Militaru, S., Mircea Coman, I., Frigy, A., Fogarasi, Z., Kocsis, I., Szabo, I. A., Fehervari, L., Nikitin, I., Resnik, E., Komissarova, M., Lazarev, V., Shebzukhova, M., Ustyuzhanin, D., Blagova, O., Alieva, I., Kulikova, V., Lutokhina, Y., Pavlenko, E., Varionchik, N., Ristic, A. D., Seferovic, P. M., Veljic, I., Zivkovic, I., Milinkovic, I., Pavlovic, A., Radovanovic, G., Simeunovic, D., Aleksic, M., Djokic, J., Hinic, S., Klasnja, S., Mircetic, K., Monserrat, L., Fernandez, X., Garcia-Giustiniani, D., Larranaga, J. M., Ortiz-Genga, M., Barriales-Villa, R., Martinez-Veira, C., Veira, E., Cequier, A., Salazar-Mendiguchia, J., Manito, N., Gonzalez, J., Fernandez-Aviles, F., Medrano, C., Yotti, R., Cuenca, S., Espinosa, M. A., Mendez, I., Zatarain, E., Alvarez, R., Garcia-Pavia, P., Briceno, A., Cobo-Marcos, M., Dominguez, F., De Teresa Galvan, E., Garcia Pinilla, J. M., Abdeselam-Mohamed, N., Lopez-Garrido, M. A., Morcillo Hidalgo, L., Ortega-Jimenez, M. V., Robles Mezcua, A., Guijarro-Contreras, A., Gomez-Garcia, D., Robles-Mezcua, M., Gimeno Blanes, J. R., Castro, F. J., Munoz Esparza, C., Sabater Molina, M., Sorli Garcia, M., Lopez Cuenca, D., Ripoll-Vera, T., Alvarez, J., Nunez, J., Gomez, Y., Sanchez Fernandez, P. L., Villacorta, E., Avila, C., Bravo, L., Diaz-Pelaez, E., Gallego-Delgado, M., Garcia-Cuenllas, L., Plata, B., Lopez-Haldon, J. E., Pena Pena, M. L., Cantero Perez, E. M., Zorio, E., Arnau, M. A., Sanz, J., Marques-Sulex, E., Cardiology, ACS - Heart failure & arrhythmias, HUS Heart and Lung Center, Clinicum, Department of Medicine, Kardiologian yksikkö, Helsinki University Hospital Area, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)
- Subjects
Registrie ,lcsh:Diseases of the circulatory (Cardiovascular) system ,EUROBSERVATIONAL RESEARCH-PROGRAM ,Dilated cardiomyopathy ,Europe ,Familial ,Genetic ,Prognosis ,Sporadic ,Adult ,Humans ,Prospective Studies ,Registries ,Cardiomyopathies ,Cardiomyopathy, Dilated ,Myocarditis ,Cardiomyopathy ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Original Research Articles ,Dilated ,PILOT ,Original Research Article ,030212 general & internal medicine ,Prospective cohort study ,Ejection fraction ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,medicine.diagnostic_test ,Guideline adherence ,3. Good health ,Cardiology and Cardiovascular Medicine ,Human ,medicine.medical_specialty ,Prognosi ,FREQUENCY ,03 medical and health sciences ,Internal medicine ,medicine ,Cardiomyopathie ,Genetic testing ,business.industry ,medicine.disease ,Prospective Studie ,lcsh:RC666-701 ,3121 General medicine, internal medicine and other clinical medicine ,Heart failure ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; AimsDilated cardiomyopathy (DCM) is a complex disease where genetics interplay with extrinsic factors. This study aims to compare the phenotype, management, and outcome of familial DCM (FDCM) and non‐familial (sporadic) DCM (SDCM) across Europe.Methods and resultsPatients with DCM that were enrolled in the prospective ESC EORP Cardiomyopathy & Myocarditis Registry were included. Baseline characteristics, genetic testing, genetic yield, and outcome were analysed comparing FDCM and SDCM; 1260 adult patients were studied (238 FDCM, 707 SDCM, and 315 not disclosed). Patients with FDCM were younger (P < 0.01), had less severe disease phenotype at presentation (P < 0.02), more favourable baseline cardiovascular risk profiles (P ≤ 0.007), and less medication use (P ≤ 0.042). Outcome at 1 year was similar and predicted by NYHA class (HR 0.45; 95% CI [0.25–0.81]) and LVEF per % decrease (HR 1.05; 95% CI [1.02–1.08]. Throughout Europe, patients with FDCM received more genetic testing (47% vs. 8%, P < 0.01) and had higher genetic yield (55% vs. 22%, P < 0.01).ConclusionsWe observed that FDCM and SDCM have significant differences at baseline but similar short‐term prognosis. Whether modification of associated cardiovascular risk factors provide opportunities for treatment remains to be investigated. Our results also show a prevalent role of genetics in FDCM and a non‐marginal yield in SDCM although genetic testing is largely neglected in SDCM. Limited genetic testing and heterogeneity in panels provides a scaffold for improvement of guideline adherence.
- Published
- 2021
6. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry
- Author
-
Lopes, Luis R, Losi, Maria-Angela, Sheikh, Nabeel, Laroche, Cécile, Charron, Philippe, Gimeno, Juan, Kaski, Juan P, Maggioni, Aldo P, Tavazzi, Luigi, Arbustini, Eloisa, Brito, Dulce, Celutkiene, Jelena, Hagege, Albert, Linhart, Ales, Mogensen, Jens, Garcia-Pinilla, José Manuel, Ripoll-Vera, Tomas, Seggewiss, Hubert, Villacorta, Eduardo, Caforio, Alida, Elliott, Perry M, Komissarova, S, Chakova, N, Niyazova, S, Linhart, A, Kuchynka, P, Palecek, T, Podzimkova, J, Fikrle, M, Nemecek, E, Bundgaard, H, Tfelt-Hansen, J, Theilade, J, Thune, J J, Axelsson, A, Mogensen, J, Henriksen, F, Hey, T, Nielsen, S K, Videbaek, L, Andreasen, S, Arnsted, H, Saad, A, Ali, M, Lommi, J, Helio, T, Nieminen, M S, Dubourg, O, Mansencal, N, Arslan, M, Tsieu, V Siam, Damy, T, Guellich, A, Guendouz, S, Tissot, C M, Lamine, A, Rappeneau, S, Hagege, A, Desnos, M, Bachet, A, Hamzaoui, M, Charron, P, Isnard, R, Legrand, L, Maupain, C, Gandjbakhch, E, Kerneis, M, Pruny, J-F, Bauer, A, Pfeiffer, B, Felix, S B, Dorr, M, Kaczmarek, S, Lehnert, K, Pedersen, A-L, Beug, D, Bruder, M, Böhm, M, Kindermann, I, Linicus, Y, Werner, C, Neurath, B, Schild-Ungerbuehler, M, Seggewiss, H, Neugebauer, A, Mckeown, P, Muir, A, Mcosker, J, Jardine, T, Divine, G, Elliott, P, Lorenzini, M, Watkinson, O, Wicks, E, Iqbal, H, Mohiddin, S, O'Mahony, C, Sekri, N, Carr-White, G, Bueser, T, Rajani, R, Clack, L, Damm, J, Jones, S, Sanchez-Vidal, R, Smith, M, Walters, T, Wilson, K, Rosmini, S, Anastasakis, A, Ritsatos, K, Vlagkouli, V, Forster, T, Sepp, R, Borbas, J, Nagy, V, Tringer, A, Kakonyi, K, Szabo, L A, Maleki, M, Bezanjani, F Noohi, Amin, A, Naderi, N, Parsaee, M, Taghavi, S, Ghadrdoost, B, Jafari, S, Khoshavi, M, Rapezzi, C, Biagini, E, Corsini, A, Gagliardi, C, Graziosi, M, Longhi, S, Milandri, A, Ragni, L, Palmieri, S, Olivotto, I, Arretini, A, Castelli, G, Cecchi, F, Fornaro, A, Tomberli, B, Spirito, P, Devoto, E, Bella, P Della, Maccabelli, G, Sala, S, Guarracini, F, Peretto, G, Russo, M G, Calabro, R, Pacileo, G, Limongelli, G, Masarone, D, Pazzanese, V, Rea, A, Rubino, M, Tramonte, S, Valente, F, Caiazza, M, Cirillo, A, Del Giorno, G, Esposito, A, Gravino, R, Marrazzo, T, Trimarco, B, Losi, M-A, Nardo, C Di, Giamundo, A, Musella, F, Pacelli, F, Scatteia, A, Canciello, G, Caforio, A, Iliceto, S, Calore, C, Leoni, L, Marra, M Perazzolo, Rigato, I, Tarantini, G, Schiavo, A, Testolina, M, Arbustini, E, Toro, A Di, Giuliani, L P, Serio, A, Fedele, F, Frustaci, A, Alfarano, M, Chimenti, C, Drago, F, Baban, A, Calò, L, Lanzillo, C, Martino, A, Uguccioni, M, Zachara, E, Halasz, G, Re, F, Sinagra, G, Carriere, C, Merlo, M, Ramani, F, Kavoliuniene, A, Krivickiene, A, Tamuleviciute-Prasciene, E, Viezelis, M, Celutkiene, J, Balkeviciene, L, Laukyte, M, Paleviciute, E, Pinto, Y, Wilde, A, Asselbergs, F W, Sammani, A, Van Der Heijden, J, Van Laake, L, De Jonge, N, Hassink, R, Kirkels, J H, Ajuluchukwu, J, Olusegun-Joseph, A, Ekure, E, Mizia-Stec, K, Tendera, M, Czekaj, A, Sikora-Puz, A, Skoczynska, A, Wybraniec, M, Rubis, P, Dziewiecka, E, Wisniowska-Smialek, S, Bilinska, Z, Chmielewski, P, Nieradko, B Foss, Michalak, E, Stepien-Wojno, M, Mazek, B, Lopes, L Rocha, Almeida, A R, Cruz, I, Gomes, A C, Pereira, A R, Brito, D, Madeira, H, Francisco, A R, Menezes, M, Moldovan, O, Guimaraes, T Oliveira, Silva, D, Ginghina, C, Jurcut, R, Mursa, A, Popescu, B A, Apetrei, E, Militaru, S, Coman, I Mircea, Frigy, A, Fogarasi, Z, Kocsis, I, Szabo, I A, Fehervari, L, Nikitin, I, Resnik, E, Komissarova, M, Lazarev, V, Shebzukhova, M, Ustyuzhanin, D, Blagova, O, Alieva, I, Kulikova, V, Lutokhina, Y, Pavlenko, E, Varionchik, N, Ristic, A D, Seferovic, P M, Veljic, I, Zivkovic, I, Milinkovic, I, Pavlovic, A, Radovanovic, G, Simeunovic, D, Zdravkovic, M, Aleksic, M, Djokic, J, Hinic, S, Klasnja, S, Mircetic, K, Monserrat, L, Fernandez, X, Garcia-Giustiniani, D, Larrañaga, J M, Ortiz-Genga, M, Barriales-Villa, R, Martinez-Veira, C, Veira, E, Cequier, A, Salazar-Mendiguchia, J, Manito, N, Gonzalez, J, Fernández-Avilés, F, Medrano, C, Yotti, R, Cuenca, S, Espinosa, M A, Mendez, I, Zatarain, E, Alvarez, R, Pavia, P Garcia, Briceno, A, Cobo-Marcos, M, Dominguez, F, Galvan, E De Teresa, Pinilla, J M García, Abdeselam-Mohamed, N, Lopez-Garrido, M A, Hidalgo, L Morcillo, Ortega-Jimenez, M V, Mezcua, A Robles, Guijarro-Contreras, A, Gomez-Garcia, D, Robles-Mezcua, M, Blanes, J R Gimeno, Castro, F J, Esparza, C Munoz, Molina, M Sabater, García, M Sorli, Cuenca, D Lopez, Ripoll-Vera, T, Alvarez, J, Nunez, J, Gomez, Y, Fernandez, P L Sanchez, Villacorta, E, Avila, C, Bravo, L, Diaz-Pelaez, E, Gallego-Delgado, M, Garcia-Cuenllas, L, Plata, B, Lopez-Haldon, J E, Pena Pena, M L, Perez, E M Cantero, Zorio, E, Arnau, M A, Sanz, J, Marques-Sule, E, Gale, Christopher Peter, Beleslin, Branko, Budaj, Andrzej, Chioncel, Ovidiu, Dagres, Nikolaos, Danchin, Nicolas, Erlinge, David, Emberson, Jonathan, Glikson, Michael, Gray, Alastair, Kayikcioglu, Meral, Maggioni, Aldo, Nagy, Klaudia Vivien, Nedoshivin, Aleksandr, Petronio, Anna-Sonia, Hesselink, Jolien Roo, Wallentin, Lars, Zeymer, Uwe, Caforio, Alida, Blanes, Juan Ramon Gimeno, Charron, Philippe, Elliott, Perry, Kaski, Juan Pablo, Maggioni, Aldo P, Tavazzi, Luigi, Tendera, Michal, Komissarova, S., Chakova, N., Niyazova, S., Linhart, A., Kuchynka, P., Palecek, T., Podzimkova, J., Fikrle, M., Nemecek, E., Bundgaard, H., Tfelt-Hansen, J., Theilade, J., Thune, J J, Axelsson, A., Mogensen, J., Henriksen, F., Hey, T., Nielsen, S K, Videbaek, L., Andreasen, S., Arnsted, H., Saad, A., Ali, M., Lommi, J., Helio, T., Nieminen, M S, Dubourg, O., Mansencal, N., Arslan, M., Tsieu, V Siam, Damy, T., Guellich, A., Guendouz, S., Tissot, C M, Lamine, A., Rappeneau, S., Hagege, A., Desnos, M., Bachet, A., Hamzaoui, M., Charron, P., Isnard, R., Legrand, L., Maupain, C., Gandjbakhch, E., Kerneis, M., Pruny, J-F, Bauer, A., Pfeiffer, B., Felix, S B, Dorr, M., Kaczmarek, S., Lehnert, K., Pedersen, A-L, Beug, D., Bruder, M., Böhm, M., Kindermann, I., Linicus, Y., Werner, C., Neurath, B., Schild-Ungerbuehler, M., Seggewiss, H., Neugebauer, A., McKeown, P., Muir, A., McOsker, J., Jardine, T., Divine, G., Elliott, P., Lorenzini, M., Watkinson, O., Wicks, E., Iqbal, H., Mohiddin, S., O'Mahony, C., Sekri, N., Carr-White, G., Bueser, T., Rajani, R., Clack, L., Damm, J., Jones, S., Sanchez-Vidal, R., Smith, M., Walters, T., Wilson, K., Rosmini, S., Anastasakis, A., Ritsatos, K., Vlagkouli, V., Forster, T., Sepp, R., Borbas, J., Nagy, V., Tringer, A., Kakonyi, K., Szabo, L A, Maleki, M., Bezanjani, F Noohi, Amin, A., Naderi, N., Parsaee, M., Taghavi, S., Ghadrdoost, B., Jafari, S., Khoshavi, M., Rapezzi, C., Biagini, E., Corsini, A., Gagliardi, C., Graziosi, M., Longhi, S., Milandri, A., Ragni, L., Palmieri, S., Olivotto, I., Arretini, A., Castelli, G., Cecchi, F., Fornaro, A., Tomberli, B., Spirito, P., Devoto, E., Bella, P Della, Maccabelli, G., Sala, S., Guarracini, F., Peretto, G., Russo, M G, Calabro, R., Pacileo, G., Limongelli, G., Masarone, D., Pazzanese, V., Rea, A., Rubino, M., Tramonte, S., Valente, F., Caiazza, M., Cirillo, A., Del Giorno, G., Esposito, A., Gravino, R., Marrazzo, T., Trimarco, B., Losi, M-A, Di Nardo, C., Giamundo, A., Musella, F., Pacelli, F., Scatteia, A., Canciello, G., Caforio, A., Iliceto, S., Calore, C., Leoni, L., Marra, M Perazzolo, Rigato, I., Tarantini, G., Schiavo, A., Testolina, M., Arbustini, E., Di Toro, A., Giuliani, L P, Serio, A., Fedele, F., Frustaci, A., Alfarano, M., Chimenti, C., Drago, F., Baban, A., Calò, L., Lanzillo, C., Martino, A., Uguccioni, M., Zachara, E., Halasz, G., Re, F., Sinagra, G., Carriere, C., Merlo, M., Ramani, F., Kavoliūnienė, Aušra, Krivickienė, Aušra, Tamulevičiūtė-Prascienė, Eglė, Vieželis, Mindaugas, Balkevičienė, Laura, Laukytė, M., Palevičiūtė, Eglė, Pinto, Y., Wilde, A., Asselbergs, F W, Sammani, A., Van Der Heijden, J., Van Laake, L., De Jonge, N., Hassink, R., Kirkels, J H, Ajuluchukwu, J., Olusegun-Joseph, A., Ekure, E., Mizia-Stec, K., Tendera, M., Czekaj, A., Sikora-Puz, A., Skoczynska, A., Wybraniec, M., Rubis, P., Dziewiecka, E., Wisniowska-Smialek, S., Bilinska, Z., Chmielewski, P., Foss-Nieradko, B., Michalak, E., Stepien-Wojno, M., Mazek, B., Lopes, L Rocha, Almeida, A R, Cruz, I., Gomes, A C, Pereira, A R, Brito, D., Madeira, H., Francisco, A R, Menezes, M., Moldovan, O., Guimaraes, T Oliveira, Silva, D., Ginghina, C., Jurcut, R., Mursa, A., Popescu, B A, Apetrei, E., Militaru, S., Coman, I Mircea, Frigy, A., Fogarasi, Z., Kocsis, I., Szabo, I A, Fehervari, L., Nikitin, I., Resnik, E., Komissarova, M., Lazarev, V., Shebzukhova, M., Ustyuzhanin, D., Blagova, O., Alieva, I., Kulikova, V., Lutokhina, Y., Pavlenko, E., Varionchik, N., Ristic, A D, Seferovic, P M, Veljic, I., Zivkovic, I., Milinkovic, I., Pavlovic, A., Radovanovic, G., Simeunovic, D., Zdravkovic, M., Aleksic, M., Djokic, J., Hinic, S., Klasnja, S., Mircetic, K., Monserrat, L., Fernandez, X., Garcia-Giustiniani, D., Larrañaga, J M, Ortiz-Genga, M., Barriales-Villa, R., Martinez-Veira, C., Veira, E., Cequier, A., Salazar-Mendiguchia, J., Manito, N., Gonzalez, J., Fernández-Avilés, F., Medrano, C., Yotti, R., Cuenca, S., Espinosa, M A, Mendez, I., Zatarain, E., Alvarez, R., Pavia, P Garcia, Briceno, A., Cobo-Marcos, M., Dominguez, F., Galvan, E De Teresa, Pinilla, J M García, Abdeselam-Mohamed, N., Lopez-Garrido, M A, Hidalgo, L Morcillo, Ortega-Jimenez, M V, Mezcua, A Robles, Guijarro-Contreras, A., Gomez-Garcia, D., Robles-Mezcua, M., Blanes, J R Gimeno, Castro, F J, Esparza, C Munoz, Molina, M Sabater, García, M Sorli, Cuenca, D Lopez, de Mallorca, Palma, Ripoll-Vera, T., Alvarez, J., Nunez, J., Gomez, Y., Fernandez, P L Sanchez, Villacorta, E., Avila, C., Bravo, L., Diaz-Pelaez, E., Gallego-Delgado, M., Garcia-Cuenllas, L., Plata, B., Lopez-Haldon, J E, Pena Pena, M L, Perez, E M Cantero, Zorio, E., Arnau, M A, Sanz, J., Marques-Sule, E., Repositório da Universidade de Lisboa, Lopes, Lr, Losi, Ma, Sheikh, N, Laroche, C, Charron, P, Gimeno, J, Kaski, Jp, Maggioni, Ap, Tavazzi, L, Arbustini, E, Brito, D, Celutkiene, J, Hagege, A, Linhart, A, Mogensen, J, Garcia-Pinilla, Jm, Ripoll-Vera, T, Seggewiss, H, Villacorta, E, Caforio, A, and Elliott, Pm
- Subjects
Genotype ,Health Policy ,Diabetes ,Cardiovascular risk factors ,Hypertension ,Hypertrophic cardiomyopathy ,Obesity ,Cardiomyopathy, Hypertrophic ,Ventricular Dysfunction, Left ,diabete ,Cardiovascular Diseases ,Risk Factors ,Heart Disease Risk Factors ,cardiovascular risk factor ,Humans ,Female ,03.02. Klinikai orvostan ,Cardiology and Cardiovascular Medicine ,Cardiomyopathies ,obesity - Abstract
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited., Aims: The interaction between common cardiovascular risk factors (CVRF) and hypertrophic cardiomyopathy (HCM) is poorly studied. We sought to explore the relation between CVRF and the clinical characteristics of patients with HCM enrolled in the EURObservational Research Programme (EORP) Cardiomyopathy registry. Methods and results: 1739 patients with HCM were studied. The relation between hypertension (HT), diabetes (DM), body mass index (BMI) and clinical traits was analyzed. Analyses were stratified according to the presence or absence of a pathogenic variant in a sarcomere gene.The prevalence of HT, DM and obesity (Ob) was 37%, 10%, and 21%, respectively. HT, DM and Ob were associated with older age (p
- Published
- 2022
7. Beta-blockers in pulmonary arterial hypertension: Time for a second thought? [Beta-blockers in pulmonary arterial hypertension: Time for a second thought?]
- Author
-
Badagliacca, R., Mercurio, V., Romeo, E., Correale, M., Masarone, D., Papa, S., Tocchetti, C.G., and Agostoni, P.
- Subjects
Beta-blockers ,Heart failure ,Pulmonary arterial hypertension ,Right ventricle ,Sympathetic system ,Settore MED/11 - Malattie dell'Apparato Cardiovascolare - Published
- 2022
8. Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure
- Author
-
Correale, M, Paolillo, S, Mercurio, V, Limongelli, G, Barilla, F, Ruocco, G, Palazzuoli, A, Scrutinio, D, Lagioia, R, Lombardi, C, Lupi, L, Magri, D, Masarone, D, Pacileo, G, Scicchitano, P, Matteo Ciccone, M, Parati, G, Tocchetti, C, Nodari, S, Correale M., Paolillo S., Mercurio V., Limongelli G., Barilla F., Ruocco G., Palazzuoli A., Scrutinio D., Lagioia R., Lombardi C., Lupi L., Magri D., Masarone D., Pacileo G., Scicchitano P., Matteo Ciccone M., Parati G., Tocchetti C. G., Nodari S., Correale, M, Paolillo, S, Mercurio, V, Limongelli, G, Barilla, F, Ruocco, G, Palazzuoli, A, Scrutinio, D, Lagioia, R, Lombardi, C, Lupi, L, Magri, D, Masarone, D, Pacileo, G, Scicchitano, P, Matteo Ciccone, M, Parati, G, Tocchetti, C, Nodari, S, Correale M., Paolillo S., Mercurio V., Limongelli G., Barilla F., Ruocco G., Palazzuoli A., Scrutinio D., Lagioia R., Lombardi C., Lupi L., Magri D., Masarone D., Pacileo G., Scicchitano P., Matteo Ciccone M., Parati G., Tocchetti C. G., and Nodari S.
- Abstract
The increasing number of patients with heart failure HF and comorbidities is due to aging population and increase of life expectancy of patients with cardiovascular disease. Encouraging results derived by recent trials may suggest some comorbidities as new targets for new drugs, highlighting the need for a better understanding of the comorbidities’ effects in HF patients and the need of a multidisciplinary approach for the management of chronic HF with comorbidities. We report a brief review about main cardiovascular and non-cardiovascular comorbidities in HF patients in order to update physicians and researchers engaged in the HF research or in “fight against heart failure.”
- Published
- 2020
9. Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. Registry
- Author
-
Salzano, A, D'Assante, R, Iacoviello, M, Triggiani, V, Rengo, G, Cacciatore, F, Maiello, C, Limongelli, G, Masarone, D, Sciacqua, A, Perrone Filardi, P, Mancini, A, Volterrani, M, Vriz, O, Castello, R, Passantino, A, Campo, M, Modesti, Pa, De Giorgi, A, Arcopinto, M, Gargiulo, P, Perticone, M, Colao, A, Milano, S, Garavaglia, A, Napoli, R, Suzuki, T, Bossone, E, Marra, Am, Cittadini, A, Saccà, L, Monti, Mg, Matarazzo, M, Stagnaro, Fm, Piccioli, L, Lombardi, A, Panicara, V, Flora, M, Golia, L, Faga, V, Ruocco, A, Della Polla, D, Franco, R, Schiavo, A, Gigante, A, Spina, E, Sicuranza, M, Monaco, F, Apicella, M, Miele, C, Campanino, Ag, Mazza, L, Abete, R, Farro, A, Luciano, F, Polizzi, R, Ferrillo, G, De Luca, M, Crisci, G, Giardino, F, Barbato, M, Ranieri, B, Ferrara, F, Russo, V, Malinconico, M, Citro, R, Guastalamacchia, E, Leone, M, Giagulli, Va, Amarelli, C, Mattucci, I, Calabrò, P, Calabrò, R, D'Andrea, A, Maddaloni, V, Pacileo, G, Scarafile, R, Belfiore, A, Cimellaro, A, Casaretti, L, Paolillo, S, Favuzzi, Amr, Di Segni, C, Bruno, C, Vergani, E, Massaro, R, Grimaldi, F, Frigo, A, Sorrentino, Mr, Malandrino, D, Manfredini, R, Fabbian, F, Puzzo, A, Ragusa, L, Caliendo, L, Carbone, L, Frigiola, A, Generali, T, Giacomazzi, F, De Vincentiis, C, Ballotta, A, Garofalo, P, Malizia, G, Misiano, G, Israr, Mz, Bernieh, D, Cassambai, S, Yazaki, Y, Heaney, Lm, Eagle, Ka, Ventura, Ho, Bruzzese, D, Salzano, Andrea, D'Assante, Roberta, Iacoviello, Massimo, Triggiani, Vincenzo, Rengo, Giuseppe, Cacciatore, Francesco, Maiello, Ciro, Limongelli, Giuseppe, Masarone, Daniele, Sciacqua, Angela, Filardi, Pasquale Perrone, Mancini, Antonio, Volterrani, Maurizio, Vriz, Olga, Castello, Roberto, Passantino, Andrea, Campo, Michela, Modesti, Pietro A, De Giorgi, Alfredo, Arcopinto, Michele, Gargiulo, Paola, Perticone, Maria, Colao, Annamaria, Milano, Salvatore, Garavaglia, Agnese, Napoli, Raffaele, Suzuki, Toru, Bossone, Eduardo, Marra, Alberto M, Cittadini, Antonio, and Misiano, Gabriella
- Subjects
Registrie ,Heart Failure ,Endocrinology, Diabetes and Metabolism ,Ventricular Dysfunction, Right ,Diabetes ,Insulins ,Socio-culturale ,Stroke Volume ,Insulin resistance ,Diabete ,Cardiopulmonary exercise test, Chronic heart failure, Diabetes, Insulin resistance, Right ventricle, TOSCA Registry ,Chronic heart failure ,Diabetes Mellitus, Type 2 ,TOSCA Registry ,Exercise Test ,Ventricular Function, Right ,Humans ,Insulin ,Right ventricle ,Registries ,Cardiology and Cardiovascular Medicine ,Cardiopulmonary exercise test ,TOSCA ,Human ,LS4_7 - Abstract
Background Findings from the T.O.S.CA. Registry recently reported that patients with concomitant chronic heart failure (CHF) and impairment of insulin axis (either insulin resistance—IR or diabetes mellitus—T2D) display increased morbidity and mortality. However, little information is available on the relative impact of IR and T2D on cardiac structure and function, cardiopulmonary performance, and their longitudinal changes in CHF. Methods Patients enrolled in the T.O.S.CA. Registry performed echocardiography and cardiopulmonary exercise test at baseline and at a patient-average follow-up of 36 months. Patients were divided into three groups based on the degree of insulin impairment: euglycemic without IR (EU), euglycemic with IR (IR), and T2D. Results Compared with EU and IR, T2D was associated with increased filling pressures (E/e′ratio: 15.9 ± 8.9, 12.0 ± 6.5, and 14.5 ± 8.1 respectively, p 2) in TD2 vs EU and IR patients was recorded (respectively, 15.8 ± 3.8 ml/Kg/min, 18.4 ± 4.3 ml/Kg/min and 16.5 ± 4.3 ml/Kg/min, p 2 in the T2D group (+ 13% increase in RV dimension, − 21% decline in TAPSE/PAPS ratio and − 20% decrease in peak VO2). Conclusion The higher risk of death and CV hospitalizations exhibited by HF-T2D patients in the T.O.S.CA. Registry is associated with progressive RV ventricular dysfunction and exercise impairment when compared to euglycemic CHF patients, supporting the pivotal importance of hyperglycaemia and right chambers in HF prognosis. Trial registration ClinicalTrials.gov identifier: NCT023358017
- Published
- 2022
10. Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry
- Author
-
Cittadini A., Salzano A., Iacoviello M., Triggiani V., Rengo G., Cacciatore F., Maiello C., Limongelli G., Masarone D., Perticone F., Cimellaro A., Filardi P. P., Paolillo S., Mancini A., Volterrani M., Vriz O., Castello R., Passantino A., Campo M., Modesti P. A., de Giorgi A., Monte I. P., Puzzo A., Ballotta A., D'Assante R., Arcopinto M., Gargiulo P., Sciacqua A., Bruzzese D., Colao A., Napoli R., Suzuki T., Eagle K. A., Ventura H. O., Marra A. M., Bossone E., Sacca L., Monti M. G., Matarazzo M., Stagnaro F. M., Piccioli L., Lombardi A., Panicara V., Flora M., Golia L., Faga V., Ruocco A., della Polla D., Franco R., Schiavo A., Gigante A., Spina E., Sicuranza M., Monaco F., Apicella M., Miele C., Campanino A. G., Mazza L., Abete R., Farro A., Luciano F., Polizzi R., Ferrillo G., de Luca M., Crisci G., Giardino F., Barbato M., Ranieri B., Ferrara F., Russo V., Malinconico M., Citro R., Guastalamacchia E., Leone M., Giagulli V. A., Amarelli C., Mattucci I., Calabro P., Calabro R., D'Andrea A., Maddaloni V., Pacileo G., Scarafile R., Belfiore A., Casaretti L., Favuzzi A. M. R., Di Segni C., Bruno C., Vergani E., Massaro R., Grimaldi F., Frigo A., Campo M. R., Sorrentino M. R., Malandrino D., Manfredini R., Fabbian F., Ragusa L., Caliendo L., Carbone L., Frigiola A., Generali T., Giacomazzi F., de Vincentiis C., Garofalo P., Malizia G., Milano S., Misiano G., Israr M. Z., Bernieh D., Cassambai S., Yazaki Y., Heaney L. M., Cittadini, Antonio, Salzano, Andrea, Iacoviello, Massimo, Triggiani, Vincenzo, Rengo, Giuseppe, Cacciatore, Francesco, Maiello, Ciro, Limongelli, Giuseppe, Masarone, Daniele, Perticone, Francesco, Cimellaro, Antonio, Perrone Filardi, Pasquale, Paolillo, Stefania, Mancini, Antonio, Volterrani, Maurizio, Vriz, Olga, Castello, Roberto, Passantino, Andrea, Campo, Michela, Modesti, Pietro A, De Giorgi, Alfredo, Monte, Ines P, Puzzo, Alfonso, Ballotta, Andrea, D'Assante, Roberta, Arcopinto, Michele, Gargiulo, Paola, Sciacqua, Angela, Bruzzese, Dario, Colao, Annamaria, Napoli, Raffaele, Suzuki, Toru, Eagle, Kim A, Ventura, Hector O, Marra, Alberto M, Bossone, Eduardo, Cittadini, A., Salzano, A., Iacoviello, M., Triggiani, V., Rengo, G., Cacciatore, F., Maiello, C., Limongelli, G., Masarone, D., Perticone, F., Cimellaro, A., Filardi, P. P., Paolillo, S., Mancini, A., Volterrani, M., Vriz, O., Castello, R., Passantino, A., Campo, M., Modesti, P. A., de Giorgi, A., Monte, I. P., Puzzo, A., Ballotta, A., D'Assante, R., Arcopinto, M., Gargiulo, P., Sciacqua, A., Bruzzese, D., Colao, A., Napoli, R., Suzuki, T., Eagle, K. A., Ventura, H. O., Marra, A. M., Bossone, E., Sacca, L., Monti, M. G., Matarazzo, M., Stagnaro, F. M., Piccioli, L., Lombardi, A., Panicara, V., Flora, M., Golia, L., Faga, V., Ruocco, A., della Polla, D., Franco, R., Schiavo, A., Gigante, A., Spina, E., Sicuranza, M., Monaco, F., Apicella, M., Miele, C., Campanino, A. G., Mazza, L., Abete, R., Farro, A., Luciano, F., Polizzi, R., Ferrillo, G., de Luca, M., Crisci, G., Giardino, F., Barbato, M., Ranieri, B., Ferrara, F., Russo, V., Malinconico, M., Citro, R., Guastalamacchia, E., Leone, M., Giagulli, V. A., Amarelli, C., Mattucci, I., Calabro, P., Calabro, R., D'Andrea, A., Maddaloni, V., Pacileo, G., Scarafile, R., Belfiore, A., Casaretti, L., Favuzzi, A. M. R., Di Segni, C., Bruno, C., Vergani, E., Massaro, R., Grimaldi, F., Frigo, A., Campo, M. R., Sorrentino, M. R., Malandrino, D., Manfredini, R., Fabbian, F., Ragusa, L., Caliendo, L., Carbone, L., Frigiola, A., Generali, T., Giacomazzi, F., de Vincentiis, C., Garofalo, P., Malizia, G., Milano, S., Misiano, G., Israr, M. Z., Bernieh, D., Cassambai, S., Yazaki, Y., and Heaney, L. M.
- Subjects
medicine.medical_specialty ,Multiple hormonal and metabolic deficiency syndrome ,Epidemiology ,Prognosi ,Anabolic deficiency ,Socio-culturale ,Heart failure ,030204 cardiovascular system & hematology ,Ventricular Function, Left ,03 medical and health sciences ,0302 clinical medicine ,Insulin resistance ,Diabetes mellitus ,Internal medicine ,Multiple hormonal ,medicine ,Clinical endpoint ,Humans ,030212 general & internal medicine ,Prospective Studies ,Registries ,TOSCA ,LS4_7 ,Ejection fraction ,business.industry ,Hazard ratio ,Metabolic deficiency syndrome ,Heart failure • Anabolic deficiency • Multiple hormonal and metabolic deficiency syndrome • Hormones • Prognosis • TOSCA ,Stroke Volume ,medicine.disease ,Prognosis ,Hormone ,Confidence interval ,Heart failure, Anabolic deficiency, Multiple hormonal and metabolic deficiency syndrome, Hormones, Prognosis, TOSCA ,Hormones ,Hospitalization ,Observational study ,Cardiology and Cardiovascular Medicine ,business - Abstract
Aims Recent evidence supports the occurrence of multiple hormonal and metabolic deficiency syndrome (MHDS) in chronic heart failure (CHF). However, no large observational study has unequivocally demonstrated its impact on CHF progression and outcome. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Treatment in Heart Failure) Registry has been specifically designed to test the hypothesis that MHDS affects morbidity and mortality in CHF patients. Methods and Results The T.O.S.CA. Registry is a prospective, multicentre, observational study involving 19 Italian centres. Thyroid hormones, insulin-like growth factor-1, total testosterone, dehydropianoandrosterone sulfate, insulin resistance, and the presence of diabetes were evaluated. A MHDS was defined as the presence of ≥2 hormone deficiencies (HDs). Primary endpoint was a composite of all-cause mortality and cardiovascular hospitalizations. Four hundred and eighty heart failure patients with ejection fraction ≤45% were enrolled. MHDS or diabetes was diagnosed in 372 patients (77.5%). A total of 271 events (97 deaths and 174 cardiovascular hospitalizations) were recorded, 41% in NO-MHDS and 62% in MHDS (P Conclusion MHDS is common in CHF and independently associated with increased all-cause mortality and cardiovascular hospitalization, representing a promising therapeutic target. Trial registration ClinicalTrials.gov identifier: NCT023358017
- Published
- 2021
11. Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry
- Author
-
Bossone, E., Arcopinto, M., Iacoviello, M., Triggiani, V., Cacciatore, F., Maiello, C., Limongelli, G., Masarone, D., Perticone, F., Sciacqua, A., Perrone-Filardi, P., Mancini, A., Volterrani, M., Vriz, O., Castello, R., Passantino, A., Campo, M., Modesti, P. A., de Giorgi, A., Monte, I., Puzzo, A., Ballotta, A., Caliendo, L., D’Assante, R., Marra, A. M., Salzano, A., Suzuki, T., Cittadini, A., Saccà, L., Monti, M. G., Napoli, R., Matarazzo, M., Stagnaro, F. M., Schiavo, A., Valente, P., Ferrara, F., Russo, V., Malinconico, M., Citro, R., Guastalamacchia, E., Leone, M., Amarelli, C., Mattucci, I., Calabrò, P., Calabrò, R., D’Andrea, A., Maddaloni, V., Pacileo, G., Scarafile, R., Belfiore, A., Cimellaro, A., Perrone Filardi, P., Casaretti, L., Paolillo, S., Gargiulo, P., Favuzzi, A. M. R., Di Segni, C., Bruno, C., Vergani, E., Massaro, R., Grimaldi, F., Frigo, A., Sorrentino, M. R., Malandrino, D., Manfredini, R., Fabbian, F., Ragusa, L., Carbone, L., Frigiola, A., Generali, T., Giacomazzi, F., de Vincentiis, C., Garofalo, P., Malizia, G., Milano, S., Misiano, G., Heaney, L. M., Bruzzese, D., Bossone E., Arcopinto M., Iacoviello M., Triggiani V., Cacciatore F., Maiello C., Limongelli G., Masarone D., Perticone F., Sciacqua A., Perrone-Filardi P., Mancini A., Volterrani M., Vriz O., Castello R., Passantino A., Campo M., Modesti P.A., De Giorgi A., Monte I., Puzzo A., Ballotta A., Caliendo L., D'Assante R., Marra A.M., Salzano A., Suzuki T., Cittadini A., Sacca L., Monti M.G., Napoli R., Matarazzo M., Stagnaro F.M., Schiavo A., Valente P., Ferrara F., Russo V., Malinconico M., Citro R., Guastalamacchia E., Leone M., Amarelli C., Mattucci I., Calabro P., Calabro R., D'Andrea A., Maddaloni V., Pacileo G., Scarafile R., Belfiore A., Cimellaro A., Casaretti L., Paolillo S., Gargiulo P., Favuzzi A.M.R., DiSegni C., Bruno C., Vergani E., Massaro R., Grimaldi F., Frigo A., Sorrentino M.R., Malandrino D., Manfredini R., DeGiorgi A., Fabbian F., Ragusa L., Carbone L., Frigiola A., Generali T., Giacomazzi F., DeVincentiis C., Garofalo P., Malizia G., Milano S., Misiano G., Heaney L.M., Bruzzese D., Bossone, E, Arcopinto, M, Iacoviello, M, Triggiani, V, Cacciatore, F, Maiello, C, Limongelli, G, Masarone, D, Perticone, F, Sciacqua, A, Perrone-Filardi, P, Mancini, A, Volterrani, M, Vriz, O, Castello, R, Passantino, A, Campo, M, A Modesti, P, De Giorgi, A, Monte, I, Puzzo, A, Ballotta, A, Caliendo, L, D'Assante, R, M Marra, A, Salzano, A, Suzuki, T, Cittadini, A, Investigators, Tosca, Bossone, E., Arcopinto, M., Iacoviello, M., Triggiani, V., Cacciatore, F., Maiello, C., Limongelli, G., Masarone, D., Perticone, F., Sciacqua, A., Perrone-Filardi, P., Mancini, A., Volterrani, M., Vriz, O., Castello, R., Passantino, A., Campo, M., Modesti, P. A., de Giorgi, A., Monte, I., Puzzo, A., Ballotta, A., Caliendo, L., D’Assante, R., Marra, A. M., Salzano, A., Suzuki, T., Cittadini, A., Saccà, L., Monti, M. G., Napoli, R., Matarazzo, M., Stagnaro, F. M., Schiavo, A., Valente, P., Ferrara, F., Russo, V., Malinconico, M., Citro, R., Guastalamacchia, E., Leone, M., Amarelli, C., Mattucci, I., Calabrò, P., Calabrò, R., D’Andrea, A., Maddaloni, V., Pacileo, G., Scarafile, R., Belfiore, A., Cimellaro, A., Perrone Filardi, P., Casaretti, L., Paolillo, S., Gargiulo, P., Favuzzi, A. M. R., Di Segni, C., Bruno, C., Vergani, E., Massaro, R., Grimaldi, F., Frigo, A., Sorrentino, M. R., Malandrino, D., Manfredini, R., Fabbian, F., Ragusa, L., Carbone, L., Frigiola, A., Generali, T., Giacomazzi, F., de Vincentiis, C., Garofalo, P., Malizia, G., Milano, S., Misiano, G., Heaney, L. M., and Bruzzese, D.
- Subjects
Male ,Anabolism ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Clinical endpoint ,Medicine ,Deficiency Disease ,030212 general & internal medicine ,Prospective Studies ,Registries ,Prospective cohort study ,Testosterone ,Anabolic deficiency ,Chronic heart failure ,Heart failure metabolism ,Multiple hormonal deficiency syndrome ,Registry ,Aged ,Biomarkers ,Chronic Disease ,Deficiency Diseases ,Disease Progression ,Female ,Heart Failure ,Humans ,Italy ,Metabolic Diseases ,Middle Aged ,Internal Medicine ,Emergency Medicine ,Human ,medicine.medical_specialty ,Anabolic deficiency, Chronic heart failure, Heart failure metabolism, Multiple hormonal deficiency syndrome, Registry ,Socio-culturale ,03 medical and health sciences ,Internal medicine ,business.industry ,Settore MED/13 - ENDOCRINOLOGIA ,Biomarker ,medicine.disease ,Metabolic Disease ,Prospective Studie ,Heart failure ,Observational study ,Hormone therapy ,business - Abstract
Recent evidence supports the concept that progression of chronic heart failure (CHF) depends upon an imbalance of catabolic forces over the anabolic drive. In this regard, multiple hormonal deficiency syndrome (MHDS) significantly has impacts upon CHF progression, and is associated with a worse clinical status and increased mortality. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Therapy in Heart Failure) Registry (clinicaltrial.gov = NCT02335801) tests the hypothesis that anabolic deficiencies reduce survival in a large population of mild-to-moderate CHF patients. The T.O.S.CA. Registry is a prospective multicenter observational study coordinated by “Federico II” University of Naples, and involves 19 centers situated throughout Italy. Thyroid hormones, insulin-like growth factor-1, total testosterone, dehydroepiandrosterone , and insulin are measured at baseline and every year for a patient-average follow-up of 3years. Subjects with CHF are divided into two groups: patients with one or no anabolic deficiency, and patients with two or more anabolic deficiencies at baseline. The primary endpoint is the composite of all-cause mortality and cardiovascular hospitalization. Secondary endpoints include the composite of all-cause mortality and hospitalization, the composite of cardiovascular mortality and cardiovascular hospitalization, and change of VO 2 peak. Patient enrollment started in April 2013, and was completed in July 2017. Demographics and main clinical characteristics of enrolled patients are provided in this article. Detailed cross-sectional results will be available in late 2018. The T.O.S.CA. Registry represents the most robust prospective observational trial on MHDS in the field of CHF. The study findings will advance our knowledge with regard to the intimate mechanisms of CHF progression and hopefully pave the way for future randomized clinical trials of single or multiple hormonal replacement therapies in CHF.
- Published
- 2017
12. Intermittent outpatient administration of levosimendan improves right ventricular-pulmonary arterial coupling in ambulatory patients with advanced heart failure
- Author
-
Melillo, E, primary, Masarone, D, additional, Valente, F, additional, Vastarella, R, additional, Gravino, R, additional, Ammendola, E, additional, Verrengia, M, additional, Caiazzo, A, additional, Petraio, A, additional, and Pacileo, G, additional
- Published
- 2021
- Full Text
- View/download PDF
13. European Cardiomyopathy Pilot Registry : EURObservational Research Programme of the European Society of Cardiology
- Author
-
Elliott P., Charron P., Blanes J. R. G., Tavazzi L., Tendera M., Konte M., Laroche C., Maggioni A. P., Anastasakis A., Arbustini E., Asselbergs F. W., Axelsson A., Brito D., Caforio A. L. P., Carr-White G., Czekaj A., Damy T., Devoto E., Favalli V., Findlay I., Garcia-Pavia P., Hagege A., Helio T., Iliceto S., Isnard R., Jansweijer J. A., Limongelli G., Linhart A., Cuenca D. L., Mansencal N., McKeown P., Mogensen J., Mohiddin S. A., Monserrat L., Olivotto I., Rapezzi C., Rigopoulos A. G., Rosmini S., Pfeiffer B., Wicks E., Podzimkova J., Kuchynka P., Palecek T., Bundgaard H., Thune J. J., Kumme A., Due Vestergaard L., Hey T., Ollila L., Kaartinen M., Dubourg O., Arslan M., Siam Tsieu M., Guellich A., Tissot C. -M., Guendouz S., Thevenin S., Cheikh Khelifa R., Gandjbakhch E., Komajda M., Neugebauer A., Steriotis A., Ritsatos K., Vlagkouli V., Biagini E., Gentile N., Longhi S., Arretini A., Fornaro A., Cecchi F., Spirito P., Formisano F., Masarone D., Valente F., Pacileo G., Schiavo A., Testolina M., Serio A., Grasso M., Wilde A., Pinto Y., Klopping C., Van Der Heijden J. F., De Jonge N., Sikora-Puz A., Wybraniec M., Francisco A. R., Madeira H., Ortiz-Genga M., Barriales-Villa R., Fernandez X., Lopez-Cuenca D., Gomez-Milanes I., Lopez-Ayala J. M., Guzzo-Merello G., Gallego-Delgado M., Muir A., McOsker J., Jardine T., Iqbal H., Sekhri N., Rajani R., Bueser T., Watkinson O., Cardiology, ACS - Amsterdam Cardiovascular Sciences, ACS - Heart failure & arrhythmias, Perry Elliott, Philippe Charron, Juan Ramon Gimeno Blane, Luigi Tavazzi, Michal Tendera, Marème Konté, Cécile Laroche, Aldo P. Maggioni, the EORP Cardiomyopathy Registry Pilot Investigators: [Aris Anastasaki, Eloisa Arbustini, Folkert W. Asselberg, Anna Axelsson, Dulce Brito, Alida L.P. Caforio, Gerald Carr-White, Agata Czekaj, Thibaud Damy, Emmanuela Devoto, Valentina Favalli, Iain Findlay, Pablo Garcia-Pavia, Albert Hagège, Tiina Heliö, Sabino Iliceto, Richard Isnard, Joeri A. Jansweijer, Giuseppe Limongelli, Ales Linhart, David López Cuenca, Nicolas Mansencal, Pascal McKeown, Jens Mogensen, Saidi A. Mohiddin, Lorenzo Monserrat, Iacopo Olivotto, Claudio Rapezzi, A.G. Rigopoulo, Stefania Rosmini, Barbara Pfeiffer, Eleanor Wicks], Elliott, P., Charron, P., Blanes, J. R. G., Tavazzi, L., Tendera, M., Konte, M., Laroche, C., Maggioni, A. P., Anastasakis, A., Arbustini, E., Asselbergs, F. W., Axelsson, A., Brito, D., Caforio, A. L. P., Carr-White, G., Czekaj, A., Damy, T., Devoto, E., Favalli, V., Findlay, I., Garcia-Pavia, P., Hagege, A., Helio, T., Iliceto, S., Isnard, R., Jansweijer, J. A., Limongelli, G., Linhart, A., Cuenca, D. L., Mansencal, N., Mckeown, P., Mogensen, J., Mohiddin, S. A., Monserrat, L., Olivotto, I., Rapezzi, C., Rigopoulos, A. G., Rosmini, S., Pfeiffer, B., Wicks, E., Podzimkova, J., Kuchynka, P., Palecek, T., Bundgaard, H., Thune, J. J., Kumme, A., Due Vestergaard, L., Hey, T., Ollila, L., Kaartinen, M., Dubourg, O., Arslan, M., Siam Tsieu, M., Guellich, A., Tissot, C. -M., Guendouz, S., Thevenin, S., Cheikh Khelifa, R., Gandjbakhch, E., Komajda, M., Neugebauer, A., Steriotis, A., Ritsatos, K., Vlagkouli, V., Biagini, E., Gentile, N., Longhi, S., Arretini, A., Fornaro, A., Cecchi, F., Spirito, P., Formisano, F., Masarone, D., Valente, F., Pacileo, G., Schiavo, A., Testolina, M., Serio, A., Grasso, M., Wilde, A., Pinto, Y., Klopping, C., Van Der Heijden, J. F., De Jonge, N., Sikora-Puz, A., Wybraniec, M., Francisco, A. R., Madeira, H., Ortiz-Genga, M., Barriales-Villa, R., Fernandez, X., Lopez-Cuenca, D., Gomez-Milanes, I., Lopez-Ayala, J. M., Guzzo-Merello, G., Gallego-Delgado, M., Muir, A., Mcosker, J., Jardine, T., Iqbal, H., Sekhri, N., Rajani, R., Bueser, T., and Watkinson, O.
- Subjects
Registrie ,Male ,Pacemaker, Artificial ,Cardiomyopathy ,Pilot Projects ,030204 cardiovascular system & hematology ,Defibrillator ,0302 clinical medicine ,Interquartile range ,Residence Characteristics ,Dilated ,Medicine ,030212 general & internal medicine ,Registries ,Age of Onset ,Non-U.S. Gov't ,Research Support, Non-U.S. Gov't ,Hypertrophic cardiomyopathy ,Dilated cardiomyopathy ,Middle Aged ,Arrhythmogenic right ventricular dysplasia ,Europe ,Multicenter Study ,cardiovascular system ,Cardiology ,Arrhythmogenic right ventricular ,Female ,Cardiology and Cardiovascular Medicine ,Cardiomyopathies ,Human ,Adult ,medicine.medical_specialty ,Registry ,Cardiotonic Agents ,Restrictive ,Observational Study ,Research Support ,Right ventricular cardiomyopathy ,NO ,03 medical and health sciences ,Age Distribution ,Internal medicine ,Journal Article ,Humans ,Cardiotonic Agent ,Pilot Project ,cardiovascular diseases ,Sex Distribution ,Cardiomyopathie ,business.industry ,Restrictive cardiomyopathy ,Hypertrophic ,medicine.disease ,Death, Sudden, Cardiac ,Residence Characteristic ,Heart failure ,business ,Defibrillators - Abstract
AIMS: Cardiomyopathies are a heterogeneous group of disorders associated with premature death due to ventricular arrhythmia or heart failure. The purpose of this study was to examine the characteristics of patients enrolled in the pilot phase of the EURObservational Research Programme (EORP) cardiomyopathy registry. METHODS AND RESULTS: Between 1 December 2012 and 30 November 2013, four cardiomyopathy phenotypes were studied: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM). Twenty-seven centres in 12 countries participated; 1115 patients were enrolled. The commonest cardiomyopathy was HCM (n = 681), followed by DCM (n = 346), ARVC (n = 59), and RCM (n = 29); 423 patients (46.4% of those reported) had familial disease; and 56 (5.0%) had rare disease phenocopies. Median age at enrolment and diagnosis was 54 [interquartile range (IQR), 42-64] and 46 years (IQR, 32-58), respectively; fewer patients with ARVC and more with RCM were diagnosed in the upper age quartile (P < 0.0001). There was a male predominance for all cardiomyopathies except RCM (P = 0.0023). Most patients were in New York Heart Association functional class I (n = 813) at enrolment; 139 (12.5%) reported syncope, most frequently in ARVC (P = 0.0009). Five hundred and seven (45.5%) patients underwent cardiac magnetic resonance imaging, 117 (10.6%) endomyocardial biopsy, and 462 (41.4%) genetic testing with a causative mutation reported in 236 individuals (51.1%). 1026 patients (92.0%) were receiving drug therapy; 316 (28.3%) had received an implantable cardioverter defibrillator (highest proportion in ARVC, P < 0.0001). CONCLUSION: This pilot study shows that services for patients with cardiomyopathy are complex, requiring access to a large range of invasive and non-invasive investigations and involvement of multidisciplinary teams. Treatment regimens are equally multifaceted and show that patients are likely to need long-term follow-up in close liaison with expert centres.
- Published
- 2016
14. USE OF CARDIAC CONTRACTILITY MODULATION: OUR EXPERIENCE
- Author
-
Lamaida, N, Masarone, D, Uran, C, and Cerciello, A
- Published
- 2024
- Full Text
- View/download PDF
15. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)
- Author
-
O'Mahony C., Jichi F., Pavlou M., Monserrat L., Anastasakis A., Rapezzi C., Biagini E., Gimeno J. R., Limongelli G., McKenna W. J., Omar R. Z., Elliott P. M., Ortiz-Genga M., Fernandez X., Vlagouli V., Stefanadis C., Coccolo F., Sandoval M. J. O., Pacileo G., Masarone D., Pantazis A., Tome-Esteban M., Dickie S., Lambiase P. D., Rahman S., O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM, Hypertrophic Cardiomyopathy Outcomes Investigators, O'Mahony, C., Jichi, F., Pavlou, M., Monserrat, L., Anastasakis, A., Rapezzi, C., Biagini, E., Gimeno, J. R., Limongelli, G., Mckenna, W. J., Omar, R. Z., Elliott, P. M., Ortiz-Genga, M., Fernandez, X., Vlagouli, V., Stefanadis, C., Coccolo, F., Sandoval, M. J. O., Pacileo, G., Masarone, D., Pantazis, A., Tome-Esteban, M., Dickie, S., Lambiase, P. D., and Rahman, S.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Prognosi ,medicine.medical_treatment ,Reproducibility of Result ,Left ventricular hypertrophy ,Ventricular tachycardia ,Risk Assessment ,sudden cardiac death ,Sudden cardiac death ,NO ,HYPERTROPHIC CARDIOMYOPATHY ,IMPLANTABLE CARDIOVERTER DEFIBRILLATOR ,Risk prediction model ,Retrospective Studie ,Internal medicine ,medicine ,cardiovascular diseases ,Proportional hazards model ,business.industry ,Hypertrophic cardiomyopathy ,Retrospective cohort study ,Cardiomyopathy, Hypertrophic ,Middle Aged ,medicine.disease ,Implantable cardioverter-defibrillator ,Death, Sudden, Cardiac ,Sample Size ,Cardiology ,Proportional Hazards Model ,Female ,Cardiology and Cardiovascular Medicine ,Risk assessment ,business ,Human - Abstract
Aims: Hypertrophic cardiomyopathy(HCM)is a leading cause of sudden cardiac death (SCD) in young adults. Current risk algorithms provide only a crude estimate of risk and fail to account for the different effect size of individual risk factors. The aim of this study was to develop and validate a new SCD risk prediction model that provides individualized risk estimates. Methods and results: The prognostic model was derived from a retrospective, multi-centre longitudinal cohort study. The model was developed fromthe entire data set using theCox proportional hazards model and internally validated using bootstrapping. The cohort consisted of 3675 consecutive patients from six centres. During a follow-up period of 24 313 patient-years (median 5.7 years), 198 patients (5%) died suddenly or had an appropriate implantable cardioverter defibrillator (ICD) shock. Of eight pre-specified predictors, age, maximal left ventricular wall thickness, left atrial diameter, left ventricular outflow tract gradient, family history of SCD, non-sustained ventricular tachycardia, and unexplained syncope were associated with SCD/appropriate ICD shock at the 15% significance level. These predictors were included in the final model to estimate individual probabilities of SCD at 5 years. The calibration slope was 0.91 (95% CI: 0.74, 1.08), C-index was 0.70 (95% CI: 0.68, 0.72), and D-statistic was 1.07 (95% CI: 0.81, 1.32). For every 16 ICDs implanted in patients with ≥4% 5-year SCD risk, potentially 1 patient will be saved from SCD at 5 years. A second model with the data set split into independent development and validation cohorts had very similar estimates of coefficients and performance when externally validated. Conclusion: This is the first validatedSCDrisk prediction model for patients withHCMand provides accurate individualized estimates for the probability of SCD using readily collected clinical parameters. ©The Author 2013.
- Published
- 2014
16. Cardiac resynchronization therapy in cardiomyopathies
- Author
-
Masarone D, Ammendola E, Del Giorno G, Colimodio F, D'Andrea A, Pacileo G, Santangelo L, Lambiase P.D., LIMONGELLI, Giuseppe, Masarone, D, Limongelli, Giuseppe, Ammendola, E, Del Giorno, G, Colimodio, F, D'Andrea, A, Pacileo, G, Santangelo, L, and Lambiase, P. D.
- Published
- 2014
17. European cardiomyopathy pilot registry: EURObservational research programme of the European society of cardiology
- Author
-
Elliott, P. Charron, P. Blanes, J.R.G. Tavazzi, L. Tendera, M. Konté, M. Laroche, C. Maggioni, A.P. Anastasakis, A. Arbustini, E. Asselbergs, F.W. Axelsson, A. Brito, D. Caforio, A.L.P. Carr-White, G. Czekaj, A. Damy, T. Devoto, E. Favalli, V. Findlay, I. Garcia-Pavia, P. Hagège, A. Heliö, T. Iliceto, S. Isnard, R. Jansweijer, J.A. Limongelli, G. Linhart, A. Cuenca, D.L. Mansencal, N. McKeown, P. Mogensen, J. Mohiddin, S.A. Monserrat, L. Olivotto, I. Rapezzi, C. Rigopoulos, A.G. Rosmini, S. Pfeiffer, B. Wicks, E. Podzimkova, J. Kuchynka, P. Palecek, T. Bundgaard, H. Thune, J.J. Kumme, A. Due Vestergaard, L. Hey, T. Ollila, L. Kaartinen, M. Dubourg, O. Arslan, M. Siam Tsieu, M. Guellich, A. Tissot, C.-M. Guendouz, S. Thevenin, S. Cheikh Khelifa, R. Gandjbakhch, E. Komajda, M. Neugebauer, A. Pfeiffer, B. Steriotis, A. Ritsatos, K. Vlagkouli, V. Biagini, E. Gentile, N. Longhi, S. Arretini, A. Fornaro, A. Cecchi, F. Spirito, P. Formisano, F. Masarone, D. Valente, F. Pacileo, G. Schiavo, A. Testolina, M. Serio, A. Grasso, M. Wilde, A. Pinto, Y. Klöpping, C. Van Der Heijden, J.F. De Jonge, N. Sikora-Puz, A. Wybraniec, M. Czekaj, A. Francisco, A.R. Brito, D. Madeira, H. Ortiz-Genga, M. Barriales-Villa, R. Fernandez, X. Lopez-Cuenca, D. Gomez-Milanes, I. Lopez-Ayala, J.M. Guzzo-Merello, G. Gallego-Delgado, M. Muir, A. McOsker, J. Jardine, T. Iqbal, H. Sekhri, N. Rajani, R. Bueser, T. Watkinson, O. on behalf of the EORP Cardiomyopathy Registry Pilot Investigators
- Abstract
Aims: Cardiomyopathies are a heterogeneous group of disorders associated with premature death due to ventricular arrhythmia or heart failure. The purpose of this study was to examine the characteristics of patients enrolled in the pilot phase of the EURObservational Research Programme (EORP) cardiomyopathy registry. Methods and results: Between 1 December 2012 and 30 November 2013, four cardiomyopathy phenotypes were studied: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM). Twenty-seven centres in 12 countries participated; 1115 patients were enrolled. The commonest cardiomyopathy was HCM (n = 681), followed by DCM (n = 346), ARVC (n = 59), and RCM (n = 29); 423 patients (46.4% of those reported) had familial disease; and 56 (5.0%) had rare disease phenocopies. Median age at enrolment and diagnosis was 54 [interquartile range (IQR), 42-64] and 46 years (IQR, 32-58), respectively; fewer patients with ARVC and more with RCM were diagnosed in the upper age quartile (P, 0.0001). There was a male predominance for all cardiomyopathies except RCM (P = 0.0023). Most patients were in New York Heart Association functional class I (n = 813) at enrolment; 139 (12.5%) reported syncope, most frequently in ARVC (P = 0.0009). Five hundred and seven (45.5%) patients underwent cardiac magnetic resonance imaging, 117 (10.6%) endomyocardial biopsy, and 462 (41.4%) genetic testing with a causative mutation reported in 236 individuals (51.1%). 1026 patients (92.0%) were receiving drug therapy; 316 (28.3%) had received an implantable cardioverter defibrillator (highest proportion in ARVC, P, 0.0001). Conclusion: This pilot study shows that services for patients with cardiomyopathy are complex, requiring access to a large range of invasive and non-invasive investigations and involvement of multidisciplinary teams. Treatment regimens are equally multifaceted and show that patients are likely to need long-term follow-up in close liaison with expert centres. © The Author 2015.
- Published
- 2016
18. 1178Percutaneous treatment of mitral insufficiency and pseudo-aneurism: a case report
- Author
-
Carbone, A, primary, Salerno, G, additional, Santoro, G, additional, Limongelli, G, additional, Vastarella, R, additional, Valente, F, additional, Gravino, R, additional, Masarone, D, additional, Verrengia, M, additional, and Pacileo, G, additional
- Published
- 2017
- Full Text
- View/download PDF
19. Heart failure: molecular, genetic and epigenetic features of the disease
- Author
-
D Alessandro, R., Roselli, T., Valente, F., Mario Iannaccone, Capogrosso, C., Petti, G., Alfano, G., Masarone, D., Ziello, B., Fimiani, F., Pacileo, G., Russo, M. G., Calabrò, P., Limongelli, G., Maddaloni, V., Calabrò, R., D'Alessandro, R, Roselli, T, Valente, F, Iannaccone, M, Capogrosso, C, Petti, G, Alfano, G, Masarone, D, Ziello, B, Fimiani, F, Pacileo, G, Russo, Maria Giovanna, Calabro', Paolo, Limongelli, Giuseppe, Maddaloni, V, and Calabrò, R.
- Subjects
Epigenomics ,Heart Failure ,Gene Expression Regulation ,Mutation ,Humans ,Gene-Environment Interaction ,Desmosomes ,Myocardial Contraction - Abstract
Factors that compete to establish heart failure (HF) are not completely known. In the last years the several technological improvements allowed us to deeply study the molecular and genetic aspects of this complex syndrome. This new approach to HF based on molecular biology new discoveries shows us more clearly the pathophysiological bases of this disease, and a future scenery where the genetics may be useful in the clinical practice, as screening of high risk populations, as well as in the diagnosis and therapy of underlying myocardial diseases. The purpose of this review was to analyse the molecular, genetic and epigenetic factors of HF. We described the molecular anatomy of the sarcomere and the pathogenesis of the heart muscle diseases, abandoning the previous monogenic theory for the concept of a polygenic disease. Different actors play a role to cause the illness by themselves, modifying the expression of the disease and, eventually, the prognosis of the patient.
- Published
- 2012
20. La Morte Cardiaca Improvvisa: cosa il cardiologo deve sapere (Sudden Cardiac Death: what a cardiologist should know)
- Author
-
Masarone D, Maddaloni V, D'Alessandro R, Valente F, Buono A, Vastarella R, Longo V, Pazzanese V, Calvanese C, Scotto Di Minico A, Gravino R, Rea A, Salerno G, Scarafile R, Del Giorno G, Ammendola E, Santangelo L, Calabro' R, Pacileo G., LIMONGELLI, Giuseppe, Masarone, D, Limongelli, Giuseppe, Maddaloni, V, D'Alessandro, R, Valente, F, Buono, A, Vastarella, R, Longo, V, Pazzanese, V, Calvanese, C, Scotto Di Minico, A, Gravino, R, Rea, A, Salerno, G, Scarafile, R, Del Giorno, G, Ammendola, E, Santangelo, L, Calabro', R, and Pacileo, G.
- Published
- 2012
21. Cardiomiopatia peripartum: problematiche gestionali in un raro caso con disfunzione bi ventricolare
- Author
-
Gravino R, Rea A, Masarone D, Salerno G, Scarafile R, Del Giorno G, Buono A, Pirozzi A, Santangelo L, Calabrò R, Pacileo G., LIMONGELLI, Giuseppe, Gravino, R, Rea, A, Masarone, D, Salerno, G, Scarafile, R, Del Giorno, G, Buono, A, Pirozzi, A, Limongelli, Giuseppe, Santangelo, L, Calabrò, R, and Pacileo, G.
- Published
- 2012
22. Nuove prospettive nella terapia dello scompenso cardiaco: Farmacogenetica, Farmacogenomica e terapia cellulare
- Author
-
D'Alessandro R, Roselli T, Capogrosso C, Iannaccone M, Valente F, Ziello, Alfano G, Petti G, Masarone D, Maddaloni V, CALABRO', Paolo, Pacileo G, RUSSO, Maria Giovanna, Calabrò R., LIMONGELLI, Giuseppe, D'Alessandro, R, Roselli, T, Capogrosso, C, Iannaccone, M, Valente, F, Ziello, Alfano, G, Petti, G, Masarone, D, Maddaloni, V, Calabro', Paolo, Pacileo, G, Russo, Maria Giovanna, Limongelli, Giuseppe, and Calabrò, R.
- Published
- 2010
23. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD)
- Author
-
O'Mahony, C. Jichi, F. Pavlou, M. Monserrat, L. Anastasakis, A. Rapezzi, C. Biagini, E. Gimeno, J.R. Limongelli, G. McKenna, W.J. Omar, R.Z. Elliott, P.M. Ortiz-Genga, M. Fernandez, X. Vlagouli, V. Stefanadis, C. Coccolo, F. Sandoval, M.J.O. Pacileo, G. Masarone, D. Pantazis, A. Tome-Esteban, M. Dickie, S. Lambiase, P.D. Rahman, S.
- Abstract
Aims: Hypertrophic cardiomyopathy(HCM)is a leading cause of sudden cardiac death (SCD) in young adults. Current risk algorithms provide only a crude estimate of risk and fail to account for the different effect size of individual risk factors. The aim of this study was to develop and validate a new SCD risk prediction model that provides individualized risk estimates. Methods and results: The prognostic model was derived from a retrospective, multi-centre longitudinal cohort study. The model was developed fromthe entire data set using theCox proportional hazards model and internally validated using bootstrapping. The cohort consisted of 3675 consecutive patients from six centres. During a follow-up period of 24 313 patient-years (median 5.7 years), 198 patients (5%) died suddenly or had an appropriate implantable cardioverter defibrillator (ICD) shock. Of eight pre-specified predictors, age, maximal left ventricular wall thickness, left atrial diameter, left ventricular outflow tract gradient, family history of SCD, non-sustained ventricular tachycardia, and unexplained syncope were associated with SCD/appropriate ICD shock at the 15% significance level. These predictors were included in the final model to estimate individual probabilities of SCD at 5 years. The calibration slope was 0.91 (95% CI: 0.74, 1.08), C-index was 0.70 (95% CI: 0.68, 0.72), and D-statistic was 1.07 (95% CI: 0.81, 1.32). For every 16 ICDs implanted in patients with ≥4% 5-year SCD risk, potentially 1 patient will be saved from SCD at 5 years. A second model with the data set split into independent development and validation cohorts had very similar estimates of coefficients and performance when externally validated. Conclusion: This is the first validatedSCDrisk prediction model for patients withHCMand provides accurate individualized estimates for the probability of SCD using readily collected clinical parameters. ©The Author 2013.
- Published
- 2014
24. RUOLO DELLA ADIPOCHINA RESISTINA NELL'INDUZIONE DELL'ESPRESSIONE DELLE MOLECOLE DI ADESIONE DA PARTE DI CELLULE ENDOTELIALI DI ARTERIA CORONARICA UMANA
- Author
-
Palmieri R., Calabrò P., Maddaloni V., Riegler L., Limongelli G., Masarone D., Roselli T., Messina S., De Rosa S., Pacileo M., Weisz S., Rucco M. A., Golino P., Calabrò R., CIRILLO, PLINIO, Palmieri, R., Calabrò, P., Maddaloni, V., Riegler, L., Limongelli, G., Masarone, D., Roselli, T., Messina, S., Cirillo, Plinio, De Rosa, S., Pacileo, M., Weisz, S., Rucco, M. A., Golino, P., and Calabrò, R.
- Subjects
cellule endoteliali ,molecole di adesione ,aterosclerosi ,resistina - Published
- 2007
25. La resistina è un’ adipocitochina in grado di indurre l’ espressione del fattore tissutale da parte di cellule endoteliali prelevate da arterie coronariche umane
- Author
-
Riegler L., Calabrò P., Maddaloni V., Palmieri R., Limongelli G., Masarone D., Roselli T., Messina S., De Rosa S., Pacileo M., Weisz S., Rucco M. A., Golino P., Calabrò R., CIRILLO, PLINIO, Riegler, L., Calabrò, P., Maddaloni, V., Palmieri, R., Limongelli, G., Masarone, D., Roselli, T., Messina, S., Cirillo, Plinio, De Rosa, S., Pacileo, M., Weisz, S., Rucco, M. A., Golino, P., and Calabrò, R.
- Subjects
trombosi ,adipochine ,Resistina ,tissue factor - Published
- 2007
26. Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group
- Author
-
Paolillo, S, Agostoni, P, Masarone, D, Corrà, U, Passino, C, Scrutinio, D, Correale, M, Cattadori, G, Metra, M, Girola, D, Piepoli, M, Salvioni, E, Giovannardi, M, Iorio, A, Emdin, M, Raimondo, R, Re, F, Cicoira, M, Belardinelli, R, Guazzi, M, Clemenza, F, Parati, G, Scardovi, A, Di Lenarda, A, La Gioia, R, Frigerio, M, Lombardi, C, Gargiulo, P, Sinagra, G, Pacileo, G, Perrone Filardi, P, Limongelli, G, Limongelli, G., PARATI, GIANFRANCO, Paolillo, S, Agostoni, P, Masarone, D, Corrà, U, Passino, C, Scrutinio, D, Correale, M, Cattadori, G, Metra, M, Girola, D, Piepoli, M, Salvioni, E, Giovannardi, M, Iorio, A, Emdin, M, Raimondo, R, Re, F, Cicoira, M, Belardinelli, R, Guazzi, M, Clemenza, F, Parati, G, Scardovi, A, Di Lenarda, A, La Gioia, R, Frigerio, M, Lombardi, C, Gargiulo, P, Sinagra, G, Pacileo, G, Perrone Filardi, P, Limongelli, G, Limongelli, G., and PARATI, GIANFRANCO
- Abstract
Background Atrial fibrillation (AF) is common in heart failure (HF). It is unclear whether AF has an independent prognostic role in HF. The aim of the present study was to assess the prognostic role of AF in HF patients with reduced ejection fraction (EF). Methods HF patients were followed in 17 centers for 3.15 years (1.51-5.24). Study endpoints were the composite of cardiovascular (CV) death and heart transplant (HTX) and all-cause death. Data analysis was performed considering the entire population and a 1 to 1 match between sinus rhythm (SR) and AF patients. Match process was done for age ± 5, gender, left ventricle EF ± 5, peakVO2 ± 3 (ml/min/kg) and recruiting center. Results A total of 3447 patients (SR = 2882, AF = 565) were included in the study. Considering the entire population, CV death and HTX occurred in 114 (20%) AF vs. 471 (16%) SR (p = 0.026) and all-cause death in 130 (23%) AF vs. 554 (19.2%) SR patients (p = 0.039). At univariable Cox analysis, AF was significantly related to prognosis. Applying a multivariable model based on all variables significant at univariable analysis (EF, peakVO2, ventilation/carbon dioxide relationship slope, sodium, kidney function, hemoglobin, beta-blockers and digoxin) AF was no longer associated with adverse outcomes. Matching procedure resulted in 338 couples. CV death and HTX occurred in 63 (18.6%) AF vs. 74 (21.9%) SR (p = 0.293) and all-cause death in 71 (21%) AF vs. 80 (23.6%) SR (p = 0.406), with no survival differences between groups. Conclusion In systolic HF AF is a marker of disease severity but not an independent prognostic indicator.
- Published
- 2015
27. Novel insights into the role of cardiotrophin-1 in cardiovascular diseases
- Author
-
Calabrò, P., primary, Limongelli, G., additional, Riegler, L., additional, Maddaloni, V., additional, Palmieri, R., additional, Golia, E., additional, Roselli, T., additional, Masarone, D., additional, Pacileo, G., additional, Golino, P., additional, and Calabrò, R., additional
- Published
- 2009
- Full Text
- View/download PDF
28. [The role of natriuretic peptides in heart failure]
- Author
-
Ancona R, LIMONGELLI, Giuseppe, Pacileo G, Miele T, Rea A, Roselli T, Masarone D, Messina S, Palmieri R, Golia E, Iacomino M, Gala S, CALABRO', Paolo, DI SALVO, Giovanni, CALABRO', Raffaele, Ancona, R, Limongelli, Giuseppe, Pacileo, G, Miele, T, Rea, A, Roselli, T, Masarone, D, Messina, S, Palmieri, R, Golia, E, Iacomino, M, Gala, S, Calabro', Paolo, DI SALVO, Giovanni, and Calabro', Raffaele
- Subjects
Heart Failure ,Ventricular Dysfunction, Left ,Natriuretic Peptide, Brain ,Humans ,Natriuretic Peptide, C-Type ,Prognosis ,Atrial Natriuretic Factor ,Biomarkers - Abstract
Over the last decades, there has been a significant increase in incidence and prevalence of heart failure, a major cause of cardiac morbidity and mortality. Measurements of neurohormones, in particular B-type natriuretic peptide (BNP), can significantly improve diagnostic accuracy, and also correlate with long-term morbidity and mortality in patients with chronic heart failure presenting to the emergency department. BNP is secreted by cardiac ventricles mainly in response to wall stress and neurohormonal factors like the sympathetic nervous system, endothelins, and the rennin-angiotensin-aldosterone system. BNP increases myocardial relaxation and oppose the vasoconstrictive, sodium retaining, and natriuretic effects caused by vasoconstrictive factors. BNP is the first biomarker to prove its clinical value for the diagnosis of left ventricular systolic and diastolic dysfunction but also for the right ventricular dysfunction, guiding prognosis and therapy management. Emerging clinical data will help further refine biomarker-guided therapeutic and monitoring strategies involving BNP.
29. Sudden death in young adults: Are myocardial bridges dangerous? | Morte improvvisa nei giovani: Esiste veramente il 'rischio dei ponti'?
- Author
-
Santella, R., Roselli, T., Masarone, D., Valente, F., Auriemma, P., Capogrosso, C., Alfano, G., Iannacone, M., Di Pasquale, L., Calabrò, P., Giuseppe LImongelli, Russo, M. G., and Calabrò, R.
30. The role of natriuretic peptides in heart failure | Ruolo dei peptidi natriuretici nello scompenso cardiaco
- Author
-
Ancona, R., Giuseppe LImongelli, Pacileo, G., Miele, T., Rea, A., Roselli, T., Masarone, D., Messina, S., Palmieri, R., Golia, E., Iacomino, M., Gala, S., Calabrò, P., Di Salvo, G., and Calabrò, R.
31. Natriuretic peptides receptors: Molecular biology, phisiology and clinical implication
- Author
-
Masarone, D., Raffaella, D. Alessandro, Buono, A., Gravino, R., Rea, A., Salerno, G., Ammendola, E., Giorno, G. D., Santangelo, L., Antonello, D. Andrea, Maria Giovanna RUSSO, Calabrò, R., Limongelli, G., and Pacileo, G.
32. Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure
- Author
-
Rocco Lagioia, Carolina Lombardi, Pietro Scicchitano, Alberto Palazzuoli, Michele Correale, Damiano Magrì, Carlo G. Tocchetti, Giuseppe Limongelli, Gianfranco Parati, Daniele Masarone, Marco Matteo Ciccone, Domenico Scrutinio, Stefania Paolillo, Giuseppe Pacileo, Savina Nodari, Valentina Mercurio, Francesco Barillà, Gaetano Ruocco, Laura Lupi, Correale, Michele, Paolillo, Stefania, Mercurio, Valentina, Limongelli, Giuseppe, Barillà, Francesco, Ruocco, Gaetano, Palazzuoli, Alberto, Scutinio, Domenico, Lagioia, Rocco, Lombardi, Carolina, Lupi, Laura, Magrì, Damiano, Masarone, Daniele, Pacileo, Giuseppe, Scicchitano, Pietro, Matteo Ciccone, Marco, Parati, Gianfranco, Tocchetti, Carlo, Nodari, Savina, Correale, M., Paolillo, S., Mercurio, V., Limongelli, G., Barilla, F., Ruocco, G., Palazzuoli, A., Scrutinio, D., Lagioia, R., Lombardi, C., Lupi, L., Magri, D., Masarone, D., Pacileo, G., Scicchitano, P., Matteo Ciccone, M., Parati, G., Tocchetti, C. G., Nodari, S., Correale, M, Paolillo, S, Mercurio, V, Limongelli, G, Barilla, F, Ruocco, G, Palazzuoli, A, Scrutinio, D, Lagioia, R, Lombardi, C, Lupi, L, Magri, D, Masarone, D, Pacileo, G, Scicchitano, P, Matteo Ciccone, M, Parati, G, Tocchetti, C, and Nodari, S
- Subjects
medicine.medical_specialty ,Population ageing ,Cardiology ,Comorbidity ,Disease ,030204 cardiovascular system & hematology ,Diabete ,Coronary artery disease ,Cardio-oncology ,Chronic heart failure ,Chronic kidney disease ,COPD ,Diabetes ,Hypertension ,Sleep apnea ,Settore MED/11 ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,mental disorders ,Internal Medicine ,medicine ,Humans ,030212 general & internal medicine ,Intensive care medicine ,Aged ,Heart Failure ,business.industry ,medicine.disease ,Italy ,Heart failure ,Chronic Disease ,Life expectancy ,business - Abstract
The increasing number of patients with heart failure HF and comorbidities is due to aging population and increase of life expectancy of patients with cardiovascular disease. Encouraging results derived by recent trials may suggest some comorbidities as new targets for new drugs, highlighting the need for a better understanding of the comorbidities’ effects in HF patients and the need of a multidisciplinary approach for the management of chronic HF with comorbidities. We report a brief review about main cardiovascular and non-cardiovascular comorbidities in HF patients in order to update physicians and researchers engaged in the HF research or in “fight against heart failure.”
- Published
- 2020
33. Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
- Author
-
Maria Angela Losi, Riccardo Alessandro, Maurizio Postorino, Federico Pieruzzi, Paolo Colomba, Sandro Feriozzi, Yuri Battaglia, Andrea Frustaci, Alessandra Testa, Ines Monte, Daniele Masarone, Serafina Sciarrino, Antonello Giordano, Antonio Pisani, Cinzia Castana, Carmine Zoccali, Elisabetta Zachara, Giuseppe Limongelli, Eleonora Riccio, Luisa Amico, Claudio Ferri, Alessandro P. Burlina, Renzo Mignani, Margherita Stefania Rodolico, Rosa Napoletano, Marina Caserta, Carmela Zizzo, Simone Scalia, Marco Spada, Roberta Oliveri, Giuseppe Cammarata, Marco Lombardi, Cristina Chimenti, Daniele Francofonte, Giovanni Duro, Maurizio Tenuta, Giuseppe Palladino, Alberto Burlina, Camillo Autore, Giulia Polo, Maurizio Pieroni, Duro, G., Zizzo, C., Cammarata, G., Burlina, A., Polo, G., Scalia, S., Oliveri, R., Sciarrino, S., Francofonte, D., Alessandro, R., Pisani, A., Palladino, G., Napoletano, R., Tenuta, M., Masarone, D., Limongelli, G., Riccio, E., Frustaci, A., Chimenti, C., Ferri, C., Pieruzzi, F., Pieroni, M., Spada, M., Castana, C., Caserta, M., Monte, I., Rodolico, M. S., Feriozzi, S., Battaglia, Y., Amico, L., Losi, M. A., Autore, C., Lombardi, M., Zoccali, C., Testa, A., Postorino, M., Mignani, R., Zachara, E., Giordano, A., Colomba, P., Duro G., Zizzo C., Cammarata G., Burlina A., Polo G., Scalia S., Oliveri R., Sciarrino S., Francofonte D., Alessandro R., Pisani A., Palladino G., Napoletano R., Tenuta M., Masarone D., Limongelli G., Riccio E., Frustaci A., Chimenti C., Ferri C., Pieruzzi F., Pieroni M., Spada M., Castana C., Caserta M., Monte I., Rodolico M.S., Feriozzi S., Battaglia Y., Amico L., Losi M.A., Autore C., Lombardi M., Zoccali C., Testa A., Postorino M., Mignani R., Zachara E., Giordano A., Colomba P., Duro, G, Zizzo, C, Cammarata, G, Burlina, A, Polo, G, Scalia, S, Oliveri, R, Sciarrino, S, Francofonte, D, Alessandro, R, Pisani, A, Palladino, G, Napoletano, R, Tenuta, M, Masarone, D, Limongelli, G, Riccio, E, Frustaci, A, Chimenti, C, Ferri, C, Pieruzzi, F, Pieroni, M, Spada, M, Castana, C, Caserta, M, Monte, I, Rodolico, M, Feriozzi, S, Battaglia, Y, Amico, L, Losi, M, Autore, C, Lombardi, M, Zoccali, C, Testa, A, Postorino, M, Mignani, R, Zachara, E, Giordano, A, and Colomba, P
- Subjects
0301 basic medicine ,Proband ,Male ,Disease ,medicine.disease_cause ,Sphingolipid ,Catalysi ,lcsh:Chemistry ,0302 clinical medicine ,Gla gene ,Fabry disease ,GLA gene ,LysoGb3 ,Medicine ,Child ,lcsh:QH301-705.5 ,Spectroscopy ,chemistry.chemical_classification ,Genetics ,Allele ,Aged, 80 and over ,Mutation ,Computer Science Applications1707 Computer Vision and Pattern Recognition ,General Medicine ,Middle Aged ,Phenotype ,3. Good health ,Computer Science Applications ,Child, Preschool ,Female ,Human ,Adult ,Adolescent ,Genotype ,Glycolipid ,Catalysis ,Article ,Inorganic Chemistry ,03 medical and health sciences ,Young Adult ,otorhinolaryngologic diseases ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,Gene ,Alleles ,Aged ,Sphingolipids ,business.industry ,Organic Chemistry ,Infant, Newborn ,Infant ,Biomarker ,gla gene ,lysogb3 ,adolescent ,adult ,aged ,aged, 80 and over ,alleles ,amino acid substitution ,biomarkers ,child ,child, preschool ,fabry disease ,female ,genotype ,glycolipids ,humans ,infant ,infant, newborn ,male ,middle aged ,phenotype ,sphingolipids ,young adult ,alpha-galactosidase ,mutation ,medicine.disease ,030104 developmental biology ,Enzyme ,chemistry ,lcsh:Biology (General) ,lcsh:QD1-999 ,Amino Acid Substitution ,alpha-Galactosidase ,Glycolipids ,business ,030217 neurology & neurosurgery ,Biomarkers - Abstract
Anderson-Fabry disease (FD) is a rare, progressive, multisystem storage disorder caused by the partial or total deficit of the lysosomal enzyme &alpha, galactosidase A (&alpha, Gal A). It is an X-linked, lysosomal enzymopathy due to mutations in the galactosidase alpha gene (GLA), encoding the &alpha, Gal A. To date, more than 900 mutations in this gene have been described. In our laboratories, the study of genetic and enzymatic alterations related to FD was performed in about 17,000 subjects with a symptomatology referable to this disorder. The accumulation of globotriaosylsphingosine (LysoGb3) was determined in blood of positives. Exonic mutations in the GLA gene were detected in 471 patients (207 Probands and 264 relatives): 71.6% of mutations were associated with the classic phenotype, 19.8% were associated with the late-onset phenotype, and 8.6% of genetic variants were of unknown significance (GVUS). The accumulation of LysoGb3 was found in all male patients with a mutation responsible for classic or late-onset FD. LysoGb3 levels were consistent with the type of mutations and the symptomatology of patients. &alpha, Gal A activity in these patients is absent or dramatically reduced. In recent years, confusion about the pathogenicity of some mutations led to an association between non-causative mutations and FD. Our study shows that the identification of FD patients is possible by associating clinical history, GLA gene analysis, &alpha, Gal A assay, and blood accumulation of LysoGB3. In our experience, LysoGB3 can be considered a reliable marker, which is very useful to confirm the diagnosis of Fabry disease.
- Published
- 2018
34. Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy
- Author
-
Giuseppe Limongelli, Emanuele Monda, Paolo Calabrò, Giuseppe Pacileo, Stefania Tramonte, Rita Gravino, Mariagiovanna Russo, Augusto Esposito, Perry M. Elliott, Ernesto Ammendola, Giulia Frisso, Daniele Masarone, Gemma Salerno, Marta Rubino, Felice Gragnano, Martina Caiazza, Limongelli, G., Monda, E., Tramonte, S., Gragnano, F., Masarone, D., Frisso, G., Esposito, A., Gravino, R., Ammendola, E., Salerno, G., Rubino, M., Caiazza, M., Russo, M., Calabro, P., Elliott, P. M., and Pacileo, G.
- Subjects
Adult ,Male ,Systemic disease ,medicine.medical_specialty ,Adolescent ,Population ,030204 cardiovascular system & hematology ,hypertrophic cardiomyopathy, red flags, genetic background ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Prevalence ,medicine ,Humans ,Clinical significance ,030212 general & internal medicine ,Family history ,Child ,education ,Aged ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Infant, Newborn ,Hypertrophic cardiomyopathy ,Infant ,Cardiomyopathy, Hypertrophic ,Middle Aged ,medicine.disease ,Cross-Sectional Studies ,Child, Preschool ,Cohort ,Etiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Electrocardiography - Abstract
Introduction: We sought to determine prevalence and predictive accuracy of clinical markers (red flags, RF), known to be associated with specific systemic disease in a consecutive cohort of patients with hypertrophic cardiomyopathy (HCM). Methods: We studied 129 consecutive patients (23.7 ± 20.9 years, range 0–74 years; male/female 68%/32%). Pre-specified RF were categorized into five domains: family history; signs/symptoms; electrocardiography; imaging; and laboratory. Sensitivity (Se), specificity (Sp), negative predictive value (NPV), positive predictive value (PPV), and predictive accuracy of RF were analyzed in the genotyped population. Results: In the overall cohort of 129 patients, 169 RF were identified in 62 patients (48%). Prevalence of RF was higher in infants (78%) and in adults >55 years old (58%). Following targeted genetic and clinical evaluation, 94 patients (74%) had a definite diagnosis (sarcomeric HCM or specific causes of HCM). We observed 14 RF in 13 patients (21%) with sarcomeric gene disease, 129 RF in 34 patients (97%) with other specific causes of HCM, and 26 RF in 15 patients (45%) with idiopathic HCM (p < 0.0001). Non-sarcomeric causes of HCM were the most prevalent in ages 55yo. Se, Sp, PPV, NPV and PA of RF were 97%, 70%, 55%, 98% and 77%, respectively. Single and clinical combination of RF (clusters) had an high specificity, NPV and predictive accuracy for the specific etiologies (syndromes/metabolic/infiltrative disorders associated with HCM). Conclusions: An extensive diagnostic work up, focused on analysis of specific diagnostic RF in patients with unexplained LVH facilitates a clinical diagnosis in 74% of patients with HCM.
- Published
- 2020
35. Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients
- Author
-
Vincenzo Russo, Ernesto Ammendola, Alessio Gasperetti, Roberta Bottino, Marco Schiavone, Daniele Masarone, Giuseppe Pacileo, Gerardo Nigro, Paolo Golino, Gregory Y. H. Lip, Antonello D'Andrea, Giuseppe Boriani, Riccardo Proietti, Russo, V., Ammendola, E., Gasperetti, A., Bottino, R., Schiavone, M., Masarone, D., Pacileo, G., Nigro, G., Golino, P., Lip, G. Y. H., D'Andrea, A., Boriani, G., and Proietti, R.
- Subjects
Pharmacology ,Heart Failure ,Aminobutyrates ,Biphenyl Compounds ,Aminobutyrate ,cardiac resynchronization therapy ,Stroke Volume ,arrhythmias ,heart failure ,sacubitril/valsartan ,ventricular remodeling ,arrhythmia ,Ventricular Function, Left ,Treatment Outcome ,Atrial Fibrillation ,Biphenyl Compound ,Humans ,Valsartan ,Cardiology and Cardiovascular Medicine ,Human - Abstract
No data on the add-on sacubitril/valsartan (S/V) therapy among cardiac resynchronization therapy with a defibrillator (CRT-D) nonresponder patients are currently available in literature. We conducted a prospective observational study including 190 CRT-D nonresponder patients with symptomatic heart failure with reduced ejection fraction despite the optimal medical therapy from at least 1 year. The primary endpoint was the rate of additional responders (left ventricular end-systolic volume reduction >15%) at 12 months from the introduction of S/V therapy. At the end of the 12 months follow-up, 37 patients (19.5%) were deemed as "additional responders" to the combination use of CRT + S/V therapy. The only clinical predictor of additional response was a lower left ventricular ejection fraction [OR 0.881 (0.815-0.953), P = 0.002] at baseline. At 12 months follow-up, there were significant improvements in heart failure (HF) symptoms and functional status [New York Heart Association 2 (2-3) vs. 1 (1-2), P < 0.001; physical activity duration/day: 10 (8-12) vs. 13 (10-18) hours, P < 0.001]. Compared with the 12 months preceding S/V introduction, there were significant reductions in the rate of HF rehospitalization (35.5% vs. 19.5%, P < 0.001), in atrial tachycardia/atrial fibrillation burden [6.0 (5.0-8.0) % vs. 0 (0-2.0) %, P < 0.001] and in the proportions of patients experiencing ventricular arrhythmias (21.6% vs. 6.3%; P < 0.001). Our results indicate that S/V add-on therapy in CRT-D nonresponder patients is associated with 19.5% of additional responders, a reduction in HF symptoms and rehospitalizations, AF burden, and ventricular arrhythmias.
- Published
- 2022
36. Beta-blockers in pulmonary arterial hypertension: Time for a second thought?
- Author
-
R. Badagliacca, V. Mercurio, E. Romeo, M. Correale, D. Masarone, S. Papa, C.G. Tocchetti, P. Agostoni, Badagliacca, R., Mercurio, V., Romeo, E., Correale, M., Masarone, D., Papa, S., Tocchetti, C. G., and Agostoni, P.
- Subjects
Pharmacology ,Heart Failure ,Pulmonary Arterial Hypertension ,Myosin Heavy Chains ,Physiology ,Hypertension, Pulmonary ,Adrenergic beta-Antagonists ,Molecular Medicine ,Humans - Abstract
Pulmonary arterial hypertension (PAH) is a heart failure syndrome characterized by right ventricular (RV) to pulmonary circulation uncoupling, counteracted by the sympathetic nervous system activation leading to β
- Published
- 2022
37. Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism
- Author
-
Giuseppe Pacileo, Arturo Cesaro, Francesco Natale, Claudia Concilio, Elisabetta Moscarella, Francesco Pelliccia, Eduardo Bossone, Marina Verrengia, Paolo Calabrò, Fabiana De Simone, Emanuele Monda, Augusto Esposito, Daniele Masarone, Vittorio Pazzanese, Giuseppe Limongelli, Martina Caiazza, Felice Gragnano, Fabio Valente, Esposito, A., Monda, E., Gragnano, F., Simone, F. D., Cesaro, A., Natale, F., Concilio, C., Moscarella, E., Caiazza, M., Pazzanese, V., Verrengia, M., Valente, F., Masarone, D., Pelliccia, F., Bossone, E., Calabro', P., Pacileo, G., and Limongelli, G.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Hyperhomocysteinemia ,hypertrophic cardiomyopathy ,homocisteine ,hyperhomocysteinaemia ,Epidemiology ,Cardiomyopathy ,MEDLINE ,Pilot Projects ,Polymorphism, Single Nucleotide ,Gastroenterology ,Polymorphism (computer science) ,Internal medicine ,Prevalence ,Humans ,Medicine ,In patient ,Methylenetetrahydrofolate Reductase (NADPH2) ,Retrospective Studies ,biology ,business.industry ,Hypertrophic cardiomyopathy ,Retrospective cohort study ,Cardiomyopathy, Hypertrophic ,Prognosis ,medicine.disease ,Methylenetetrahydrofolate reductase ,biology.protein ,Female ,Cardiology and Cardiovascular Medicine ,business - Published
- 2020
38. Epidemiology and Clinical Aspects of Genetic Cardiomyopathies
- Author
-
Daniele Masarone, Juan Pablo Kaski, Perry M. Elliott, Giuseppe Pacileo, Giuseppe Limongelli, Sharlene M. Day, Eduardo Bossone, Masarone, Daniele, Kaski, Juan Pablo, Pacileo, Giuseppe, Elliott, Perry M., Bossone, Eduardo, Day, Sharlene M., Limongelli, Giuseppe, Masarone, D, Kaski, Jp, Pacileo, G, Elliott, Pm, Bossone, E, Day, Sm, and Limongelli, G
- Subjects
Genetic Markers ,0301 basic medicine ,medicine.medical_specialty ,Standard of care ,Disease stages ,Disease ,030204 cardiovascular system & hematology ,Global Health ,Sudden death ,03 medical and health sciences ,Restrictive cardiomyopathy ,0302 clinical medicine ,Clinical registry ,Epidemiology ,medicine ,Humans ,Intensive care medicine ,business.industry ,Clinical course ,Genetic Therapy ,General Medicine ,Hypertrophic cardiomyopathy ,Nonischemic dilated cardiomyopathy ,Natural history ,Phenotype ,030104 developmental biology ,Morbidity ,Cardiomyopathies ,Arrhythmogenic right ventricular cardiomyopathy ,Cardiology and Cardiovascular Medicine ,business - Abstract
Cardiomyopathies (CMPs) are an increasingly recognized cause of heart failure and sudden death, particularly in young patients. Since their original description, major advances were achieved in the phenotype knowledge, natural history, and nosography of CMPs leading to different classification systems and therapies. However, a deeper knowledge of different causes, genotype-phenotype link, and natural history in different disease stages (preclinical, overt disease, and end-stage disease) according to a recognized standard of care (ie, international guidelines) is needed. Clinical registries can fill gaps in our knowledge regarding the uncovered issues on cause, clinical course, and management of CMPs.
- Published
- 2018
39. Berlin Heart EXCOR® pediatric ventricular assist device in a patient with Sotos syndrome: a case report
- Author
-
Maria Giovanna Russo, Marina Verrengia, Danilo De Paulis, Giuseppe Limongelli, Daniele Masarone, Andrea Petraio, Ciro Maiello, Rita Gravino, Giuseppe Pacileo, Gravino, R., Limongelli, G., Petraio, A., Masarone, D., Russo, M. G., Maiello, C., Verrengia, M., De Paulis, D., and Pacileo, G.
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Biventricular assist device ,lcsh:Medicine ,Case Report ,Disease ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,In patient ,Craniofacial ,Child ,Contraindication ,NSD1 gene ,Sotos Syndrome ,Berlin Heart EXCOR® pediatric ventricular assist device ,business.industry ,Sotos syndrome ,lcsh:R ,General Medicine ,medicine.disease ,030220 oncology & carcinogenesis ,Ventricular assist device ,Circulatory system ,Cardiology ,Heart Transplantation ,Female ,Heart-Assist Devices ,business ,Human - Abstract
Introduction Berlin Heart EXCOR® pediatric ventricular assist device is a mechanical circulatory support device currently used in pediatric patients. Sotos syndrome is a well-described multiple anomaly syndrome characterized by overgrowth, distinctive craniofacial appearance, cardiac abnormalities, and variable learning disabilities. Case presentation We describe a 7-year-old female Caucasian child with classic Sotos syndrome features subjected to implantation of Berlin Heart EXCOR® pediatric biventricular assist device mechanical support. A heart transplant was carried out after a support time of 459 days. After 5 years of follow-up, our patient is clinically stable and the performance of the transplanted heart is excellent. Conclusion This case confirms that Berlin Heart EXCOR® pediatric ventricular assist device can provide satisfactory and safe circulatory support for children with end-stage heart diseases, even in those with Sotos syndrome. The syndrome is not a contraindication to implantation, since the complications are the same as those observed in patients without the syndrome and the prognosis is not affected by the disease.
- Published
- 2018
40. Diagnostic clues for the diagnosis of nonsarcomeric hypertrophic cardiomyopathy (Phenocopies): Amyloidosis, fabry disease, and mitochondrial disease
- Author
-
Giuseppe Pacileo, Gemma Salerno, Franco Cecchi, Silvia Castelletti, Tommaso Marrazzo, Antonio Pisani, Marina Verrengia, Perry M. Elliott, Daniele Masarone, Giuseppe Limongelli, Rita Gravino, Marta Rubino, Limongelli, G., Masarone, D., Verrengia, M., Gravino, R., Salerno, G., Castelletti, S., Rubino, M., Marrazzo, T., Pisani, A., Cecchi, F., Elliott, P., Pacileo, G., Limongelli, Giuseppe, Masarone, Daniele, Verrengia, Marina, Gravino, Rita, Salerno, Gemma, Castelletti, Silvia, Rubino, Marta, Marrazzo, Tommaso, Pisani, Antonio, Cecchi, Franco, Elliott, Perry, and Pacileo, Giuseppe
- Subjects
Pathology ,medicine.medical_specialty ,Fabry disease ,business.industry ,Amyloidosis ,Mitochondrial disease ,Hypertrophic cardiomyopathy ,Disease ,030204 cardiovascular system & hematology ,medicine.disease ,hypertrophic cardiomyopathy ,03 medical and health sciences ,Heart disorder ,0302 clinical medicine ,medicine ,Etiology ,Amyloidosi ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Differential diagnosis ,Cardiology and Cardiovascular Medicine ,business - Abstract
Hypertrophic cardiomyopathy (HCM) is the most common known inherited heart disorder, with a prevalence of 1: 500 of the adult population. Etiology of HCM can be heterogeneous, with sarcomeric gene disease as the leading cause in up to 60% of the patients, and with a number of possible different diseases (phenocopies) in about 10%-15% of the patients. Early diagnosis of storage and infiltrative disorders, particularly those with specific treatments (i.e., Fabry disease and/or amyloidosis), means early management and treatment, with a significant impact on patients prognosis. Here, we report on four different cases of HCM, highlighting difficulties to make differential diagnosis of different forms of cardiomyopathies, and their potential impact on the management.
- Published
- 2018
41. Exercise speckle-tracking strain imaging demonstrates impaired right ventricular contractile reserve in hypertrophic cardiomyopathy
- Author
-
Gianluigi Tagliamonte, Rossella Vastarella, Antonello D'Andrea, Luca Baldini, Enza Di Palma, Eduardo Bossone, Marina Verrengia, Giuseppe Limongelli, Daniele Masarone, Andreina Carbone, Giuseppe Pacileo, Lucia Riegler, Raffaele Calabrò, Maria Giovanna Russo, D'Andrea, A, Limongelli, G, Baldini, L, Verrengia, M, Carbone, A, Di Palma, E, Vastarella, R, Masarone, D, Tagliamonte, G, Riegler, L, Calabro, R, Russo, Mg, Bossone, E, Pacileo, G, D'Andrea, Antonello, Limongelli, Giuseppe, Baldini, Luca, Verrengia, Marina, Carbone, Andreina, Di Palma, Enza, Vastarella, Rossella, Masarone, Daniele, Tagliamonte, Gianluigi, Riegler, Lucia, Calabrã², Raffaele, Russo, Maria Giovanna, Bossone, Eduardo, and Pacileo, Giuseppe
- Subjects
Male ,Longitudinal strain ,Ventricular Dysfunction, Right ,Entire right ventricle ,030204 cardiovascular system & hematology ,Severity of Illness Index ,Strain ,0302 clinical medicine ,Reference Values ,030212 general & internal medicine ,Observer Variation ,Ejection fraction ,Hypertrophic cardiomyopathy ,Middle Aged ,Exercise capacity ,Fractional Flow Reserve, Myocardial ,Echocardiography ,cardiovascular system ,Cardiology ,Right ventricle ,Female ,Cardiology and Cardiovascular Medicine ,Wall thickness ,Echocardiography, Stress ,Adult ,medicine.medical_specialty ,Diastolic function ,Rest ,Speckle tracking strain ,Young Adult ,03 medical and health sciences ,Internal medicine ,Image Interpretation, Computer-Assisted ,medicine ,Exercise stress echo ,Humans ,cardiovascular diseases ,business.industry ,Contractile reserve ,Exercise stress ,Cardiomyopathy, Hypertrophic ,medicine.disease ,Myocardial Contraction ,Echocardiography, Doppler, Color ,ROC Curve ,Case-Control Studies ,Multivariate Analysis ,Linear Models ,business - Abstract
Aims To analyse right ventricular (RV) systolic function in patients with hypertrophic cardiomyopathy (HCM) at rest and during exercise, and its possible correlation with left ventricular(LV) morphology and function.Methods and results: Standard echo, exercise stress echo, and RV 2D speckle-tracking strain (2DSE) were performed in 45 patients with HCM and in 45 age- and sex-comparable healthy controls. RV global longitudinal strain (GLS) was calculated by averaging local strains along the entire right ventricle. LV mass index and WS wall thickness were significantly increased in HCM, while LV ejection fraction, RV diameters, RV tissue Doppler systolic peak and the RV end-systolic pressure-area relationship at rest were comparable between the two groups. Conversely, all transmittal Doppler indexes were significantly impaired in HCM. In addition, RV GLS and regional peak myocardial RV strains were significantly reduced in patients with HCM (all P
- Published
- 2017
42. Genetics of Takotsubo Syndrome
- Author
-
Giuseppe Limongelli, Daniele Masarone, Fiorella Fratta, Spinelli Barrile Ludovica, Adelaide Fusco, Maria Giovanna Russo, Paolo Calabrò, Francesca Pisacane, Giuseppe Pacileo, Valeria Maddaloni, Roberta Pacileo, Annapaola Cirillo, Eduardo Bossone, Marta Rubino, Guido Coppola, Raffaele Calabrò, Limongelli, G, Masarone, D, Maddaloni, V, Rubino, M, Fratta, F, Cirillo, A, Ludovica, Sb, Pacileo, R, Fusco, A, Coppola, Gr, Pisacane, F, Bossone, E, Calabro, P, Calabro, R, Russo, Mg, Pacileo, G, Limongelli, Giuseppe, Masarone, Daniele, Maddaloni, Valeria, Rubino, Marta, Fratta, Fiorella, Cirillo, Annapaola, Ludovica, Spinelli Barrile, Pacileo, Roberta, Fusco, Adelaide, Coppola, Guido Ronald, Pisacane, Francesca, Bossone, Eduardo, Calabro', Paolo, Calabro', Raffaele, Russo, Maria Giovanna, and Pacileo, Giuseppe
- Subjects
G-Protein-Coupled Receptor Kinase 5 ,Candidate gene ,Estrogen receptor ,Disease ,030204 cardiovascular system & hematology ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Takotsubo Cardiomyopathy ,Receptors, Adrenergic, alpha-1 ,Genetic predisposition ,Humans ,Medicine ,Genetic Predisposition to Disease ,030212 general & internal medicine ,Catecholamine-induced myocardial toxicity ,Receptor ,Genetics ,Takotsubo syndrome ,Polymorphism, Genetic ,business.industry ,General Medicine ,Adrenoceptor polymorphism ,Receptors, Adrenergic, beta-2 ,Receptors, Adrenergic, beta-1 ,Cardiology and Cardiovascular Medicine ,business - Abstract
Takotsubo syndrome (TTS) is an enigmatic disease with a multifactorial and still unresolved pathogenesis. A genetic predisposition has been suggested based on the few familial TTS cases. Conflicting results have been published regarding the role of functional polymorphisms in relevant candidate genes, such as α1-, β1-, and β2-adrenergic receptors; G protein-coupled receptor kinase 5; and estrogen receptors. Further research is required to help clarify the role of genetic susceptibility in TTS.
- Published
- 2016
43. Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group
- Author
-
Marco Metra, Angela Beatrice Scardovi, Francesco Clemenza, Marco Guazzi, Giuseppe Limongelli, Federica Re, Claudio Passino, Piergiuseppe Agostoni, Rosa Raimondo, Massimo F Piepoli, Maria Frigerio, Romualdo Belardinelli, Domenico Scrutinio, Stefania Paolillo, Andrea Di Lenarda, Daniele Masarone, Rocco La Gioia, Davide Girola, Marta Giovannardi, Gianfranco Parati, Gaia Cattadori, Michele Correale, Pasquale Perrone-Filardi, Giuseppe Pacileo, Michele Emdin, Mariantonietta Cicoira, Gianfranco Sinagra, Paola Gargiulo, Carlo Lombardi, Annamaria Iorio, Elisabetta Salvioni, Ugo Corrà, Paolillo, S, Agostoni, P, Masarone, D, Corrà, U, Passino, C, Scrutinio, D, Correale, M, Cattadori, G, Metra, M, Girola, D, Piepoli, M, Salvioni, E, Giovannardi, M, Iorio, A, Emdin, M, Raimondo, R, Re, F, Cicoira, M, Belardinelli, R, Guazzi, M, Clemenza, F, Parati, G, Scardovi, A, Di Lenarda, A, La Gioia, R, Frigerio, M, Lombardi, C, Gargiulo, P, Sinagra, G, Pacileo, G, Perrone Filardi, P, Limongelli, G, Piepoli, Mf, Iorio, Annamaria, Scardovi, Ab, DI LENARDA, Andrea, Sinagra, Gianfranco, Limongelli, G., Paolillo, Stefania, Agostoni, Piergiuseppe, Masarone, Daniele, Corrà, Ugo, Passino, Claudio, Scrutinio, Domenico, Correale, Michele, Cattadori, Gaia, Metra, Marco, Girola, Davide, Piepoli, Massimo F, Salvioni, Elisabetta, Giovannardi, Marta, Emdin, Michele, Raimondo, Rosa, Re, Federica, Cicoira, Mariantonietta, Belardinelli, Romualdo, Guazzi, Marco, Clemenza, Francesco, Parati, Gianfranco, Scardovi, Angela B, Di Lenarda, Andrea, La Gioia, Rocco, Frigerio, Maria, Lombardi, Carlo, Gargiulo, Paola, Pacileo, Giuseppe, PERRONE FILARDI, Pasquale, Limongelli, Giuseppe, Piepoli, Massimo F., Scardovi, Angela B., and Perrone Filardi, Pasquale
- Subjects
Male ,medicine.medical_specialty ,Digoxin ,Prognosi ,Left ,Renal function ,Heart failure ,Matching analysi ,Kaplan-Meier Estimate ,Severity of Illness Index ,Regression Analysi ,Ventricular Function, Left ,Atrial fibrillation ,MECKI score ,Matching analysis ,Prognosis ,Aged ,Atrial Fibrillation ,Biomarkers ,Chronic Disease ,Female ,Heart Failure ,Hospitalization ,Humans ,Middle Aged ,Multivariate Analysis ,Regression Analysis ,Internal medicine ,medicine ,Clinical endpoint ,Internal Medicine ,Ventricular Function ,Sinus rhythm ,Multivariate Analysi ,Ejection fraction ,business.industry ,Biomarker ,medicine.disease ,medicine.anatomical_structure ,Ventricle ,Cardiology ,business ,medicine.drug ,Human - Abstract
Background Atrial fibrillation (AF) is common in heart failure (HF). It is unclear whether AF has an independent prognostic role in HF. The aim of the present study was to assess the prognostic role of AF in HF patients with reduced ejection fraction (EF). Methods HF patients were followed in 17 centers for 3.15 years (1.51–5.24). Study endpoints were the composite of cardiovascular (CV) death and heart transplant (HTX) and all-cause death. Data analysis was performed considering the entire population and a 1 to 1 match between sinus rhythm (SR) and AF patients. Match process was done for age ± 5, gender, left ventricle EF ± 5, peakVO 2 ± 3 (ml/min/kg) and recruiting center. Results A total of 3447 patients (SR = 2882, AF = 565) were included in the study. Considering the entire population, CV death and HTX occurred in 114 (20%) AF vs. 471 (16%) SR (p = 0.026) and all-cause death in 130 (23%) AF vs. 554 (19.2%) SR patients (p = 0.039). At univariable Cox analysis, AF was significantly related to prognosis. Applying a multivariable model based on all variables significant at univariable analysis (EF, peakVO 2 , ventilation/carbon dioxide relationship slope, sodium, kidney function, hemoglobin, beta-blockers and digoxin) AF was no longer associated with adverse outcomes. Matching procedure resulted in 338 couples. CV death and HTX occurred in 63 (18.6%) AF vs. 74 (21.9%) SR (p = 0.293) and all-cause death in 71 (21%) AF vs. 80 (23.6%) SR (p = 0.406), with no survival differences between groups. Conclusion In systolic HF AF is a marker of disease severity but not an independent prognostic indicator.
- Published
- 2015
44. Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction
- Author
-
Scrutinio, Domenico, Agostoni, Piergiuseppe, Gesualdo, Loreto, Corra, Ugo, Mezzani, Alessandro, Piepoli, Massimo, Di Lenarda, Andrea, Iorio, Annamaria, Passino, Claudio, Magri, Damiano, Masarone, Daniele, Battaia, Elisa, Girola, Davide, Re, Federica, Cattadori, Gaia, Parati, Gianfranco, Sinagra, Gianfranco, Villani, Giovanni Quinto, LIMONGELLI, Giuseppe, Pacileo, Giuseppe, Guazzi, Marco, Metra, Marco, Frigerio, Maria, Cicoira, Mariantonietta, Miná, Chiara, Malfatto, Gabriella, Caravita, Sergio, Bussotti, Maurizio, Salvioni, Elisabetta, Veglia, Fabrizio, Correale, Michele, Scardovi, Angela B., Emdin, Michele, Giannuzzi, Pantaleo, Gargiulo, Paola, Giovannardi, Marta, Perrone Filardi, Pasquale, Raimondo, Rosa, Ricci, Roberto, Paolillo, Stefania, Farina, Stefania, Belardinelli, Romualdo, Passantino, Andrea, La Gioia, Rocco, Fiorentini, Cesare, Apostolo, Anna, Palermo, Pietro, Contini, Mauro, Bertella, Erika, Mantegazza, Valentina, Pietrucci, Francesca, Ferraironi, Aessandro, Casenghi, Matteo, Clemenza, Francesco, Roselli, Teo, Buono, Andrea, Santoro, Daniela, Campanale, Saba, Caputo, Domenica, Bertipaglia, Donatella, Vaninetti, Raffaella, Confalonieri, Marco, Zambon, Elena, Berton, Emanuela, Torregiani, Chiara, Cas, Livio Dei, Carubelli, Valentina, Binno, Simone, Marchese, Giovanni, Oliva, Fabrizio, Pastormerlo, Luigi, CALABRO', Raffaele, Scrutinio, Domenico, Agostoni, Piergiuseppe, Gesualdo, Loreto, Corra, Ugo, Mezzani, Alessandro, Piepoli, Massimo, Di Lenarda, Andrea, Iorio, Annamaria, Passino, Claudio, Magri, Damiano, Masarone, Daniele, Battaia, Elisa, Girola, Davide, Re, Federica, Cattadori, Gaia, Parati, Gianfranco, Sinagra, Gianfranco, Villani, Giovanni Quinto, Limongelli, Giuseppe, Pacileo, Giuseppe, Guazzi, Marco, Metra, Marco, Frigerio, Maria, Cicoira, Mariantonietta, Miná, Chiara, Malfatto, Gabriella, Caravita, Sergio, Bussotti, Maurizio, Salvioni, Elisabetta, Veglia, Fabrizio, Correale, Michele, Scardovi, Angela B., Emdin, Michele, Giannuzzi, Pantaleo, Gargiulo, Paola, Giovannardi, Marta, Perrone Filardi, Pasquale, Raimondo, Rosa, Ricci, Roberto, Paolillo, Stefania, Farina, Stefania, Belardinelli, Romualdo, Passantino, Andrea, La Gioia, Rocco, Fiorentini, Cesare, Apostolo, Anna, Palermo, Pietro, Contini, Mauro, Bertella, Erika, Mantegazza, Valentina, Pietrucci, Francesca, Ferraironi, Aessandro, Casenghi, Matteo, Clemenza, Francesco, Roselli, Teo, Buono, Andrea, Calabro', Raffaele, Santoro, Daniela, Campanale, Saba, Caputo, Domenica, Bertipaglia, Donatella, Vaninetti, Raffaella, Confalonieri, Marco, Zambon, Elena, Berton, Emanuela, Torregiani, Chiara, Cas, Livio Dei, Carubelli, Valentina, Binno, Simone, Marchese, Giovanni, Oliva, Fabrizio, Pastormerlo, Luigi, Corrà, Ugo, Lenarda, Andrea Di, Magrì, Damiano, Minà, Chiara, Scrutinio, D, Agostoni, P, Gesualdo, L, Corra, U, Mezzani, A, Piepoli, M, Di Lenarda, A, Iorio, A, Passino, C, Magri, D, Masarone, D, Battaia, E, Girola, D, Re, F, Cattadori, G, Parati, G, Sinagra, G, Villani, G, Limongelli, G, Pacileo, G, Guazzi, M, Metra, M, Frigerio, M, Cicoira, M, Miná, C, Malfatto, G, Caravita, S, Bussotti, M, Salvioni, E, Veglia, F, Correale, M, Scardovi, A, Emdin, M, Giannuzzi, P, Gargiulo, P, Giovannardi, M, Perrone Filardi, P, Raimondo, R, Ricci, R, Paolillo, S, Farina, S, Belardinelli, R, Passantino, A, La Gioia, R, Fiorentini, C, Apostolo, A, Palermo, P, Contini, M, Bertella, E, Mantegazza, V, Pietrucci, F, Ferraironi, A, Casenghi, M, Clemenza, F, Roselli, T, Buono, A, Calabrò, R, Santoro, D, Campanale, S, Caputo, D, Bertipaglia, D, Vaninetti, R, Confalonieri, M, Zambon, E, Berton, E, Torregiani, C, Cas, L, Carubelli, V, Binno, S, Marchese, G, Oliva, F, Pastormerlo, L, Scardovi, Angela B, and PERRONE FILARDI, Pasquale
- Subjects
Adult ,Male ,medicine.medical_specialty ,Kidney Disease ,Aged ,Chronic Disease ,Female ,Follow-Up Studies ,Humans ,Kidney Function Tests ,Middle Aged ,Exercise ,Heart Failure ,Kidney Diseases ,Oxygen Consumption ,Stroke Volume ,Prognosi ,medicine.medical_treatment ,Renal function ,Settore MED/11 - Malattie dell'Apparato Cardiovascolare ,Heart failure ,Follow-Up Studie ,Peak exercise oxygen consumption ,Prognosis ,Cardiology and Cardiovascular Medicine ,Internal medicine ,medicine ,Heart transplantation ,Ejection fraction ,Kidney Function Test ,business.industry ,Hazard ratio ,Atrial fibrillation ,General Medicine ,Stroke volume ,medicine.disease ,heart failure, exercise capacity, renal function ,exercise capacity ,Cardiology ,business ,Kidney disease ,Human - Abstract
Background: Chronic kidney disease is associated with sympathetic activation and muscle abnormalities, which may contribute to decreased exercise capacity. We investigated the correlation of renal function with peak exercise oxygen consumption (V˙O2) in heart failure (HF) patients. Methods and Results: We recruited 2,938 systolic HF patients who underwent clinical, laboratory, echocardiographic and cardiopulmonary exercise testing. The patients were stratified according to estimated glomerular filtration rate (eGFR). Mean follow-up was 3.7 years. The primary outcome was a composite of cardiovascular death and urgent heart transplantation at 3 years. On multivariable regression, eGFR was predictor of peakV˙O2 (P
- Published
- 2015
45. Pathogenesis of Takotsubo Syndrome
- Author
-
Adelaide Fusco, Paolo Calabrò, Fiorella Fratta, Annapaola Cirillo, Raffaele Calabrò, Marta Rubino, Valeria Maddaloni, Guido Coppola, Daniele Masarone, Ludovica Spinelli Barrile, Roberta Pacileo, Maria Giovanna Russo, Giuseppe Pacileo, Francesca Pisacane, Edoardo Bossone, Masarone, D, Maddaloni, V, Rubino, M, Fratta, F, Cirillo, A, Barrile, L, Pacileo, R, Fusco, A, Coppola, G, Pisacane, F, Calabro, P, Calabro, R, Bossone, E, Russo, Mg, and Pacileo, G
- Subjects
catecholamine induced myocardial toxicity ,lcsh:Diseases of the circulatory (Cardiovascular) system ,medicine.medical_specialty ,Takotsubo syndrome ,Membrane permeability ,business.industry ,Disease ,Hypoxia (medical) ,Bioinformatics ,pathophysiology ,Pathophysiology ,Pathogenesis ,Endocrinology ,lcsh:RC666-701 ,Internal medicine ,medicine ,Catecholamine ,General Earth and Planetary Sciences ,medicine.symptom ,Acute stress ,business ,General Environmental Science ,medicine.drug - Abstract
Takotsubo syndrome (TTS) is an enigmatic disease with a multifactorial and still unresolved pathogenesis. Postulated mechanisms include catecholamine excess, coronary artery spasm, and microvascular dysfunction, however catecholamines seem to play a central role in the pathophysiology of TTS. In facts catecholamines have relevant effects on the vasculature and myocardium. Toxic direct effects of catecholamine on myocardium are mediated by multiple pathway including functional hypoxia, metabolic changes and changes in membrane permeability leading to various electrolytic imbalances. Recently report of familial cases has suggested a genetic component. Further research is required to help clarify the proposed hypotheses and to increase our understanding of the cardiovascular responses to acute stress and the pathophysiology underpinning TTS.
- Published
- 2017
46. Right Ventricular Cardiomyopathies: A Multidisciplinary Approach to Diagnosis
- Author
-
Aris Anastasakis, Giuseppe Limongelli, Russo Maria Giovanna, Perry M. Elliott, Raffaele Calabrò, M. Paola Francalanci, Giuseppe Pacileo, Alessandra Rea, Daniele Masarone, Eduardo Bossone, Limongelli, Giuseppe, Rea, A, Masarone, D, Francalanci, Mp, Anastasakis, A, Calabro', R, Maria Giovanna, R, Bossone, E, Elliott, Pm, Pacileo, G., Limongelli, G, Giovanna, Rm, and Pacileo, G
- Subjects
Diagnostic Imaging ,Heart Defects, Congenital ,Male ,medicine.medical_specialty ,Cardiac Catheterization ,Heart disease ,Sarcoidosis ,Ventricular Dysfunction, Right ,Endomyocardial fibrosis ,Cardiomyopathy ,Magnetic Resonance Imaging, Cine ,Muscle disorder ,Sudden death ,Diagnosis, Differential ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Arrhythmogenic Right Ventricular Dysplasia ,Cardiomyopathy, Restrictive ,Ejection fraction ,business.industry ,medicine.disease ,Endomyocardial Fibrosis ,Echocardiography, Doppler ,medicine.anatomical_structure ,Ventricle ,Cardiology ,Ventricular Function, Right ,Female ,Differential diagnosis ,Cardiology and Cardiovascular Medicine ,business ,Tomography, X-Ray Computed - Abstract
The physiological importance of the right ventricle (RV) has been underestimated over the past years. Finally in the early 1950s through the 1970s, cardiac surgeons recognized the importance of RV function. Since then, the importance of RV function has been recognized in many acquired cardiac heart disease. RV can be mainly or together with left ventricle (LV) affected by inherited or acquired cardiomyopathy. In fact, RV morphological and functional remodeling occurs more common during cardiomyopathies than in ischemic cardiomyopathies and more closely parallels LV dysfunction. Moreover, there are some cardiomyopathy subtypes showing a predominant or exclusive involvement of the RV, and they are probably less known by cardiologists. The clinical approach to right ventricular cardiomyopathies is often challenging. Imaging is the first step to raise the suspicion and to guide the diagnostic process. In the differential diagnosis, cardiologists should consider athlete's heart, congenital heart diseases, multisystemic disorders, and inherited arrhythmias. However, a multiparametric and multidisciplinary approach, involving cardiologists, experts in imaging, geneticists, and pathologists with a specific expertise in these heart muscle disorders is required.
- Published
- 2014
47. Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist
- Author
-
Eduardo Bossone, Giuseppe Pacileo, Alessandra Rea, Enrica Golia, Rita Gravino, Lucio Santangelo, Raffaele Calabrò, Andrea Buono, Daniele Masarone, Giuseppe Limongelli, Raffaella D’Alessandro, Giuseppe Del Giorno, Ernesto Ammendola, Gemma Salerno, Maria Giovanna Russo, D'Alessandro, R, Masarone, D, Buono, A, Gravino, R, Rea, A, Salerno, G, Golia, E, Ammendola, E, Del Giorno, G, Santangelo, L, Russo, Maria Giovanna, Calabro', Raffaele, Bossone, E, Pacileo, G, Limongelli, Giuseppe, Russo, Mg, Calabrò, R, and Limongelli, G.
- Subjects
medicine.medical_specialty ,Sympathetic nervous system ,medicine.drug_class ,Volume overload ,Cardiology ,Adrenergic ,Diuresis ,Bioinformatics ,Natriuresis ,Internal medicine ,Natriuretic peptide ,Medicine ,Humans ,Natriuretic Peptides ,Heart Failure ,business.industry ,medicine.disease ,Prognosis ,Pathophysiology ,Endocrinology ,medicine.anatomical_structure ,Heart failure ,Disease Progression ,Molecular Medicine ,Cardiology and Cardiovascular Medicine ,business ,Biomarkers - Abstract
Natriuretic peptides (NPs) counter the effects of volume overload or adrenergic activation of the cardiovascular system. They are able to induce arterial vasodilatations, natriuresis and diuresis, and they reduce the activities of the renin–angiotensin–aldosterone system and the sympathetic nervous system. However, in addition to wall stress, other factors have been associated with elevated natriuretic peptide levels. Since 2000, because of their characteristics, NPs have become quantitative plasma biomarkers of heart failure. Nowadays, NPs play an important role not only in the diagnosis of heart failure, but also for a prognostic purpose and a guide to medical therapy. Finally, a new drug that modulates the NP system or recombinant analogs of NPs are now available in patients with heart failure.
- Published
- 2013
48. Takotsubo Cardiomyopathy Do the Genetics Matter?
- Author
-
Giuseppe, Limongelli, Raffaella, D'Alessandro, Daniele, Masarone, Valeria, Maddaloni, Olga, Vriz, Rosalba, Minisini, Rodolfo, Citro, Paolo, Calabrò, Maria Giovanna, Russo, Raffaele, Calabrò, Giuseppe, Pacileo, Eduardo, Bossone, Perry Mark, Elliott, Limongelli, G, D'Alessandro, R, Masarone, D, Maddaloni, V, Vriz, O, Minisini, R, Citro, R, Calabro, P, Russo, Mg, Calabro, R, Pacileo, G, Bossone, E, Elliott, Pm, Limongelli, Giuseppe, Calabro', Paolo, Russo, Maria Giovanna, Calabro', Raffaele, and Elliott, P. M.
- Subjects
Mice ,Polymorphism, Genetic ,Takotsubo Cardiomyopathy ,Animals ,Humans ,Female - Abstract
Takotsubo cardiomyopathy (TTC) is an enigmatic disease with a multifactorial and still unresolved pathogenesis. Recent experimental and clinical observation has suggested a role for genetics in the pathogenesis of TTC. Ethnic as well as seasonal variation in the prevalence of TTC is well described, but it is only recently that familial cases of TTC have been reported. In recent years technological advances in exome capture and DNA sequencing have offered clinicians a new opportunity to discover genetics-related disease. This article explores the role of genetic mechanisms that might explain or modulate the pathogenesis of TTC.
- Published
- 2013
49. Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course
- Author
-
Giuseppe Limongelli, Daniele Masarone, Raffaella D’Alessandro, Perry M. Elliott, Limongelli, Giuseppe, Masarone, D, D'Alessandro, R, and Elliott, P. M.
- Subjects
Cardiomyopathy, Dilated ,medicine.medical_specialty ,Mitochondrial Diseases ,Genetic counseling ,Coronary Artery Disease ,Mitochondrion ,DNA, Mitochondrial ,Coronary artery disease ,Internal medicine ,medicine ,Humans ,Myocytes, Cardiac ,Endothelial dysfunction ,Organ system ,business.industry ,Myocardium ,Hypertrophic cardiomyopathy ,Clinical course ,Cardiomyopathy, Hypertrophic ,medicine.disease ,Mitochondria ,Diagnosis treatment ,Mutation ,Cardiology ,Molecular Medicine ,Endothelium, Vascular ,Cardiology and Cardiovascular Medicine ,business - Abstract
The mitochondrion is the main site of production of ATP that represents the source of energy for a large number of cellular processes. Mitochondrial diseases that result in a deficit in ATP production can affect almost every organ system with a large spectrum of clinical phenotypes. Cardiomyocytes are particularly vulnerable to limited ATP supply because of their large energy requirement. Abnormalities in the mitochondrial function are increasingly recognized in association with dilated and hypertrophic cardiomyopathy, cardiac conduction defects, endothelial dysfunction and coronary artery disease. Cardiologists should, therefore, be alerted to symptoms and signs suggestive of mitochondrial diseases and become familiar with the general issues related to multisystem disease management, genetic counseling and testing.
- Published
- 2012
50. Effect of cardiac resynchronization therapy on cardiotrophin-1 circulating levels in patients with heart failure
- Author
-
Maria Giovanna Russo, Antonello D'Andrea, Daniele Masarone, Lucia Riegler, Rita Gravino, Raffaella Scarafile, Giovanni Di Salvo, Lucio Santangelo, T. Miele, T. Roselli, Giuseppe Limongelli, Massimo Romano, Raffaele Calabrò, Paolo Calabrò, Valeria Maddaloni, Gemma Salerno, Giuseppe Pacileo, Limongelli, Giuseppe, Roselli, T, Pacileo, G, Calabro', Paolo, Maddaloni, V, Masarone, D, Riegler, L, Gravino, R, Scarafile, R, Salerno, G, Miele, T, D'Andrea, A, Santangelo, L, Romano, M, DI SALVO, Giovanni, Russo, Maria Giovanna, and Calabró, R.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cardiotrophin 1 ,medicine.medical_treatment ,Cardiomyopathy ,Cardiac resynchronization therapy ,Doppler echocardiography ,Cardiac Resynchronization Therapy ,Internal medicine ,Internal Medicine ,Medicine ,Humans ,cardiovascular diseases ,Ventricular remodeling ,Aged ,Heart Failure ,medicine.diagnostic_test ,Ventricular Remodeling ,business.industry ,Heart failure ,Cytokines ,Echocardiography, Doppler ,Exercise Test ,Female ,Middle Aged ,Doppler ,medicine.disease ,medicine.anatomical_structure ,Ventricle ,Echocardiography ,cardiovascular system ,Emergency Medicine ,Cardiology ,Sample collection ,business ,circulatory and respiratory physiology - Abstract
Cardiotrophin-1 (CT-1) is a member of the interleukin (IL-6) family of cytokines. Plasma CT-1 levels correlate with the left ventricle mass index in patients with dilatated cardiomyopathy and congestive heart failure (CHF). The aim of this paper was to evaluate CT-1 plasma levels, before and after cardiac resynchronization therapy CRT, and to characterizeits prognostic role in patients with CHF. Fifty-two consecutive patients (M/F = 39/13; 56 ± 11 years old) underwent clinical and echocardiographic evaluation, and blood sample collection at baseline. The same evaluation was repeated 6.4 ± 0.79 months after CRT. Patients with a decreased LV end-systolic volume by at least 15% (reverse remodeling) were considered echo responders to CRT. Twenty-nine patients (56%) were responders to CRT. After CRT, only 15 patients (29%) showed increased CT-1 after CRT. They were all non responders to CRT. A multivariate, logistic model showed CT-1 as an independent predictor of CRT echo response (p = 0.005; OR 0.97). During follow-up (18 ± 7 months), 21 cardiac events in 18 patients occurred. A Cox multivariable model showed plasma BNP pre-CRT (p = 0.02; CI 1.2-5.6; OR 3.1) and CT1 post-CRT (p = 0.01; CI 1.4-4.3; OR 2.7) as independent predictors of cardiac events. Analysis of CT-1 plasma levels deserves future consideration for larger, longitudinal studies in patients with CHF.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.